

# **Cyclopharm Limited Annual Report 2011**

**Cyclopharm Limited and its Controlled Entities  
ABN 74 116 931 250**

cyclopharm

# Contents

|                                           |           |
|-------------------------------------------|-----------|
| <b>FINANCIAL HIGHLIGHTS</b>               | <b>2</b>  |
| <b>CHAIRMAN'S LETTER</b>                  | <b>3</b>  |
| <b>MANAGING DIRECTOR'S REVIEW</b>         | <b>5</b>  |
| <b>DIRECTORS' REPORT</b>                  | <b>10</b> |
| <b>AUDITOR'S INDEPENDENCE DECLARATION</b> | <b>24</b> |
| <b>CORPORATE GOVERNANCE</b>               | <b>25</b> |
| <b>STATEMENT OF COMPREHENSIVE INCOME</b>  | <b>36</b> |
| <b>STATEMENT OF FINANCIAL POSITION</b>    | <b>37</b> |
| <b>STATEMENT OF CASH FLOWS</b>            | <b>38</b> |
| <b>STATEMENT OF CHANGES IN EQUITY</b>     | <b>39</b> |
| <b>NOTES</b>                              | <b>40</b> |
| <b>DIRECTOR'S DECLARATION</b>             | <b>86</b> |
| <b>INDEPENDENT AUDIT REPORT</b>           | <b>87</b> |
| <b>ASX ADDITIONAL INFORMATION</b>         | <b>89</b> |
| <b>GENERAL INFORMATION</b>                | <b>90</b> |


## FINANCIAL HIGHLIGHTS

| Full Year ending 31 December |        | 2009   | 2010  | 2011    | % Change |
|------------------------------|--------|--------|-------|---------|----------|
| Sales Revenue                | \$'000 | 11,099 | 9,465 | 10,315  | 8.98%    |
| Net Profit/(Loss) Before Tax | \$'000 | 2,568  | 808   | (1,192) | NA       |
| Net Profit/(Loss) After Tax  | \$'000 | 2,044  | 450   | (956)   | NA       |
| EPS                          | cents  | 1.20   | 0.26  | (0.55)  | NA       |


| Sales Revenue for the Full Year ending 31 December |        | 2009   | 2010  | 2011   | % Change |
|----------------------------------------------------|--------|--------|-------|--------|----------|
| Technegas Division                                 | \$'000 | 11,099 | 9,443 | 9,466  | 0.25%    |
| Molecular Imaging Division                         | \$'000 | -      | 22    | 849    | 3787.24% |
| Total Sales Revenue                                | \$'000 | 11,099 | 9,465 | 10,315 | 8.99%    |

| Net Profit/(Loss) Before Tax for the Full Year ending 31 December |        | 2009  | 2010  | 2011    | % Change |
|-------------------------------------------------------------------|--------|-------|-------|---------|----------|
| Technegas Division                                                | \$'000 | 2,568 | 1,672 | 1,616   | (3.4%)   |
| Molecular Imaging Division                                        | \$'000 | -     | (864) | (2,808) | (224.8%) |
| Total Net Profit/(Loss) Before Tax                                | \$'000 | 2,568 | 808   | (1,192) | NA       |

**Sales by Region: 2010**



**Sales by Region: 2011**



# Chairman's Letter



27 March 2012

Dear Shareholder

The 2011 calendar year was an extremely challenging year for your company and whilst some very positive developments took place, the overall result of a loss after tax of \$956,220 is extremely disappointing. Shareholders will appreciate, however, that the poor result was primarily attributed to the losses suffered by our newly-formed Molecular Imaging group, Cyclopet. Cyclopet was adversely impacted by aggressive competition from government-owned enterprises. Our Managing Director, Mr James McBrayer, has done an excellent job of highlighting these issues with the appropriate regulatory authorities and we are confident that we will end up with a very favourable outcome. We are presently waiting for a report from the Australian Government's Productivity Commission which should enable us to compete on an even footing with ANSTO.

The Technegas division was also adversely impacted by movements in foreign currencies as the rapid increase in the value of the Australian dollar has reduced the profitability of this business as the great majority of its income comes from medical equipment exports. Nevertheless, a profit of \$1.62 million before tax is very satisfactory in all the circumstances and this business continues to develop. We have some exciting new product refinements coming on the market over the next 12 months which will enhance this business.

It was very gratifying to achieve a major milestone in obtaining from the United States Food and Drug Administration (FDA) protocol endorsement of our Phase 3 Clinical Trial and in December 2011 the FDA gave final clearance that will allow us to start recruiting patients. It is quite extraordinary that this process has taken the best part of 20 years! Since 1986 Technegas has helped over 2.6 million patients, without adverse side effects, suffering from the life-threatening condition, Pulmonary Embolism. Technegas products are used in every major market throughout the globe with the exception of the United States. Shareholders will appreciate that the United States represents 50% of the nuclear medicine departments in the world. Penetration into this market is expected to more than double our international demand for Technegas. We are hopeful that by 2015 we will have a commercial presence in the United States and be able to replicate the growth of our business that we have achieved in Canada. Canada now represents the second-largest market for Technegas in the world.

Shareholders will also be aware that we have an involvement in Macquarie Medical Imaging (MMI) a comprehensive imaging facility including PET (Positron Emission Tomography). The imaging practice is housed within Macquarie University Hospital located at North Ryde, NSW. MMI is now starting to show the promise that we anticipated when the investment was undertaken. We now have a 30% equity partner in Macquarie Medical Imaging in the form of Macquarie University itself while we hold a 20% equity interest.

Perhaps the highlight of the year has been the emerging opportunities in radio-pharmaceuticals which have come out of our cyclotron business at Macquarie.

Sometimes when I reflect upon the challenges and difficulties of Cyclopharm I am mindful of the so-called *Stockdale Paradox*. Admiral James Stockdale was the most highly decorated officer in the United States Navy who was held in captivity in North Vietnam in very poor conditions for around eight years. He said: *Optimists give up because they don't confront the brutal facts. Pessimists give up because they can only see brutal facts and not a glorious future to work towards.* In many ways I believe that Cyclopharm exemplifies the *Stockdale Paradox* and I am confident that ultimately Cyclopharm will be a highly successful company.

# Chairman's Letter

Continued



I would like to thank our management and staff, led by our Managing Director, Mr James McBrayer, whose persistence and commitment to delivering on the company's objectives has been exemplary. I also want to thank Mr John Sharman who was a former Managing Director of the company who has stepped down as a director because of the pressure of his other commitments. We also thank our bankers and customers for their support. Finally, I want to thank shareholders for their patience and belief in the company as was exemplified by many shareholders participating in the recent rights issue.

Yours faithfully,



**Vanda Gould**  
Chairman

# Managing Director's Review



## Features

As a result of the substantial milestones that we delivered at the close of 2010, I am pleased to inform shareholders that Cyclopharm Limited ("Cyclopharm" or "the Company") can no longer be considered a one product company. Firstly, our cyclotron facility at Macquarie University Hospital ("MUH") has just completed its first full year of operations since receiving Australian Therapeutic Goods Authority licensing in December 2010. Secondly, Macquarie Medical Imaging ("MMI"), our joint venture diagnostic imaging service located at Macquarie University Hospital continues to expand. Despite a slower than expected ramp up, we are now encouraged by the growth in patient volumes seen through the department.

While we have expanded our overall offering, Technegas remains the financial foundation of the group, recording 92% of sales for the year. Although the new business ventures deliver diversity to our product and service offering, as expected, both CycloPet and MMI as start-up ventures have negatively impacted our financial performance. The following table outlines the group's consolidated performance on a comparative year financial basis:

| Full Year ended 31 December               | 2010   | 2011    |
|-------------------------------------------|--------|---------|
|                                           | \$'000 | \$'000  |
| Net Profit / (Loss) Before Tax            | 808    | (1,192) |
| Add back: MMI share of loss of associate  | (311)  | (583)   |
| Add back: Molecular Imaging Division loss | (553)  | (2,225) |
| Technegas Division Net Profit Before Tax  | 1,672  | 1,616   |

The Molecular Imaging business contributed revenues of \$849,051 (2010: \$21,842) and a Loss after tax of \$2,623,072 (2010: \$864,385). We are disappointed with the financial performance of the Molecular Imaging business. The lower than expected profitability is primarily attributed to two factors. Firstly, Cyclopet, our Positron Emission Tomography ("PET") radiopharmaceutical production facility has been faced with fierce competition from government owned enterprises.

Secondly, the slower than expected ramp-up of Macquarie University Hospital required additional investment in support of MMI, our joint venture imaging group. MMI provides state of the art imaging facilities including 3T MRI, CT, X-ray, Mammography, Ultrasound and PET imaging as well as interventional radiology for the new hospital located on the campus of Macquarie University and neighbouring suburbs.

During the year, Cyclopharm made an additional investment of \$400,000 into MMI bringing the total investment to \$900,000 (2010: \$500,000). The share of the loss in MMI recognised in the current year was \$583,273 (2010: \$311,372). In December 2011, Macquarie University Hospital became a 30% shareholder in MMI. Cyclopharm has maintained its 20% shareholding with the remaining 50% held by Alfred Health Solutions Pty Ltd.

The combined sales of the Company's key products TechnegasPlus generators (Generators) and Patient Administration Sets (PAS), of \$9.47m was consistent with the prior year amount of \$9.44m. Both Technegas Generator units and revenues were consistent with that of the prior year.

The sale of Patient Administration Sets (PAS) boxes were 4% higher even though revenue was consistent with the prior year. In 2009 and 2010, the global shortage of Molybdenum 99 ("Mo99") had an impact on all nuclear medicine procedures throughout the world. Mo99 is the isotope used to produce Sodium Pertechnetate Tc99m (Tc99m). Tc99m is the radioactive starting material that is used in the production of Technegas. Technegas sales rebounded in 2011 as global production levels of Molybdenum 99 returned to normal.

Unfavourable foreign currency movements impacted revenue as approximately 72% of sales are denominated in currencies other than the Australian Dollar.

For the reasons mentioned above, the Company reported a loss after tax of \$956,220 (2010: profit after tax of \$450,106).

# Managing Director's Review

## Continued




### Operating review

#### Technegas


Technegas is a lung imaging device used primarily to diagnose the presence of blood clots in the lungs known as Pulmonary Emboli (PE). For the last 20 years, over 2,600,000 patients have benefited from the Technegas system. The company faced similar challenges as in prior years with continued competition from Computed Tomography Pulmonary Angiogram ("CTPA"). In spite of these hurdles, Technegas has demonstrated its relevance and has once again generated strong sales and cash flows. This was further assisted by global production levels of Molybdenum 99 returning to normal. In 2009 and 2010, global molybdenum shortage had dampened demand for all nuclear medicine products.

#### Revenue Composition

Sales revenue of \$9.47m from the Company's key products, Generators and PAS, were consistent with the preceding year (2010: \$9.46m). Despite a 4% increase in units sold of 169,750 units (2010: 162,800 units), PAS or consumable revenue was consistent at \$7.35 million for the current period compared to that of the previous year (2010: \$7.36 million).



Cyclopharm recorded 55 TechnegasPlus Generator sales in 2011, which is consistent with the prior year (2010: 54). Sales into Asia were disappointing with 3 generators sold during the year (2010: 12 generators). Technegas generator and other sales revenues of \$2.13m were consistent with the prior year (2010: \$2.08m). The impact of higher volumes and flat sales resulted in lower margins as compared to the prior year. This variation is primarily attributed to foreign exchange movements in the Euro to Australian dollar. Furthermore, the weighted average of revenue generated in Europe was consistent at 61% as compared to 60% in 2010.



#### New Drug Application to sell Technegas in the USA

As previously advised in an announcement to the ASX on 13 December 2011, the much awaited entry into the United States Market was tangibly advanced by receiving approval from the United States Food and Drug Administration (FDA) on our proposed clinical trial protocol parameters. The significance of attaining Special Protocol Assessment approval is equivalent to achieving a contract with the FDA on the most critical element of any New Drug Application.

# Managing Director's Review

## Continued



As the USA represents such a major growth opportunity, the Directors will be prudent in pursuing approval to sell Technegas in the USA.

### Regional Review

#### Europe


Approximately 61% of sales revenue is derived in Europe (2010: 60%). Overall sales revenue was consistent at \$5.65m (2010: \$5.57m). Pleasingly, generator sales were higher with 31 sold in 2011 compared with 25 in the prior year while 1,981 PAS boxes were sold, 9% higher than the 1,811 boxes sold in 2010. Sales revenue was however impacted by an approximate 8% movement in the Australian dollar relative to the European Euro.

#### North America

North America recorded sales of 8 generators, double the number of generators sold in the previous year (2010: 4). We are very pleased to report PAS sales continue to grow in this region with the 8<sup>th</sup> consecutive year of growth being recorded. 688 PAS boxes were sold in 2011 as compared to the previous year (2010: 658 PAS boxes). With a total revenue of \$1.69m recorded in 2011, Canada has surpassed Australia and is now our second single largest market in the world. The Directors have been extremely pleased with the success of Technegas in Canada. We see this success as a strong indicator to the potential growth for Technegas in the United States once marketing approval is achieved.

#### Asia Pacific

Revenues in the Asia Pacific region were consistent with 2010. In Australia, where Technegas enjoys a very high market share, total revenues fell marginally by 4% despite consistent generator sales of 10 units and a 7% growth in the number of PAS boxes sold. In Asia, sales revenue dropped by 72%. In 2010, sales to Hong Kong and China drove the increase in revenues of 101% over the prior year. As noted in 2010 Annual Report, this trend was not expected to continue at such a rapid rate. The substantial decrease was also due to the delay in receiving new regulatory approval following the natural disasters in Japan during 2011 and the introduction of a new regulatory approval process. We expect strong sales growth in Japan once approval is received.



# Managing Director's Review

## Continued



### Molecular Imaging

CycloPet moved from a development to a commercial phase in 2011. During its first full year of operations, sales generated from the cyclotron facility located at Macquarie University Hospital was \$0.85m (2010: \$0.02m). An overall loss before tax of \$2,807,782 was recorded for the period (2010: loss of \$864,385). While it is pleasing to see the facility commercially operational, the revenue growth has been lower than originally expected.

The underperformance is predominantly linked to competition from government funded enterprises operating in the NSW market. To address this market imbalance in August 2011, Cyclopharm lodged a formal complaint with the Australian Government Competitive Neutrality Complaints Office, a division within the Productivity Commission specifically charged with investigating complaints against Government owned enterprises. The outcome of this investigation is anticipated to be released at the beginning of April 2012.

Despite the current competitive irregularities in the marketplace, Positron Emission Tomography continues to represent an area of growth within the field of diagnostic imaging. In July 2011, the Federal Government announced the expansion of items reimbursed by the Medicare Benefit Scheme. Furthermore, the July announcement relaxed some of the restrictions imposed on service providers. As a result, we expect to see a growth in Private Sector providers involved in this cutting edge technology.

### Macquarie Medical Imaging

Cyclopharm's medical imaging joint venture has now been in operation for 18 months. MMI is the most technologically advanced imaging centre in Australia and with its close ties with the Australian School of Advanced Medicine represents a fully aligned and integrated diagnostic, therapeutic and research platform.

MMI provides patients at Macquarie University Hospital and neighbouring suburbs access to state of the art imaging facilities including 3T MRI, CT, X-ray, Ultrasound and Positron Emission Tomography (PET) diagnostic imaging as well as interventional radiology services.

Due to Cyclopharm's minority shareholding, profit and losses are recorded as an equity accounted investment. As a result, revenues are not reported in our accounts. The group's shared losses of MMI amounted to \$583,273 (2010: loss of \$311,372). Losses are the direct result of the slower than expected ramp-up of Macquarie University Hospital. No further losses will be recorded in Cyclopharm's financial results as the investment in MMI has been fully written down as at 31 December 2011.

### OUTLOOK

In 2012, your Directors expect continued growth in Technegas revenues from both targeted marketing in Europe as well as growth following regulatory approval in Japan and Russia. We forecast a change in the mix of Technegas products. We anticipate more generators (lower margins) relative to PAS box sales and therefore lower profit margins.

We look forward to introducing Technegas to the United States market through our Phase 3 clinical trial scheduled to commence by Q2 2012. Investigational sites will be progressively added throughout 2012 and 2013 to meet the target of 750 patients. Over half of the world's nuclear medicine departments are located in the United States and represents the single biggest growth opportunity for Technegas.

Leveraged off our Cyclopet diversification strategy, in 2011 management initiated some Research and Development initiatives that represent some exciting commercial potential for your company. I look forward to sharing the details of these initiatives in the coming months once our Intellectual Property rights are secured through patent protection.

While the market for PET radiopharmaceuticals manufactured by Cyclopet is growing, the market has not reached our initial expectations. The Directors maintain their view that the Cyclotron facility is a major investment that will yield significant long term returns for the Company but recognise that the interim working capital shortfall will require funding from the Technegas business. Part of the proceeds from the capital raising exercise completed in December 2011 will be used to fund the operations of the Molecular

# Managing Director's Review

## Continued

Imaging Division. The lagging market combined with competition from government owned enterprises requires additional capital to support this new venture.

We forecast that 2012's profitability will continue to be adversely impacted by the issues faced by Cyclopet.

Notwithstanding the above, I wish to express my gratitude to my staff and management team, and our trading partners. I also take this opportunity to note my appreciation to the Chairman, Mr Vanda Gould, and my fellow Directors, Mr David Heaney and Mr John Sharman who has resigned on 29 February 2012. Lastly I want to thank you, our Shareholders for your continued support and patience.



**James McBrayer**  
Managing Director and CEO

# Directors' Report



The Directors of Cyclopharm submit their report for the year ended 31 December 2011.

## DIRECTORS

The names and details of the Company's Directors in office during the financial year and until the date of this report are as follows. Directors were in office for this entire year unless otherwise stated.

### Names, qualifications, experience and special responsibilities

#### **Mr V R Gould – Non Executive Chairman**

*M Com, FCA, FCPA, B Com*

Mr Gould has been a member of the Board since 21 November 2005. He is currently the Group Non-Executive Chairman appointed 1 March 2007 and also serves as Chairman of the Audit, Board Nominations, and Remuneration Committees of the Group.

Mr Gould has broad business experience having practiced as a chartered accountant for more than 30 years. As founding Chairman in 1984 of CVC Limited (listed on the ASX) he has overseen investments in several companies involved in the health services/medical industries including Cyclopharm. He is also chairman of Vita Life Sciences Limited (listed on the ASX) and several other private and public companies and educational establishments.

Mr Gould lives in Sydney and is 63 years old.

#### **Mr J M McBrayer – Managing Director and Company Secretary**

*BSP Pharm, GDM, FAICD, AIM*

Mr McBrayer has been a member of the Board since 3 June 2008 at which time he accepted the role of Managing Director. Mr McBrayer serves as a member of the Board Nominations Committee.

Mr McBrayer has more than 25 years experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr McBrayer held the role of Managing Director at Lipa Pharmaceuticals, Australia's largest contract manufacturer of over-the-counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's largest radioactive diagnostic and therapeutic pharmaceutical provider.

Mr McBrayer lives in Sydney and is 46 years old.

# Directors' Report

## Continued

### DIRECTORS (CONTINUED)

#### **Mr D J Heaney – Non Executive Director (Independent)**

Mr Heaney was appointed to the Cyclopharm Board on 20 November 2007. David serves as a member of the Audit, Remuneration and Board Nominations Committees.

Mr Heaney is currently an executive director of Thompson Partners Pty Ltd and a non-executive director of Colorpak Limited (since 24 January 2004). Mr Heaney also served as a director of Mariner Financial Limited between 27 May 2005 and 12 May 2009 and as a director of Dromana Estate Limited between 10 July 2009 and 15 December 2011.

Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in senior management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US.

Mr Heaney lives in Melbourne and is 67 years old.

#### **Mr J S Sharman – Non Executive Director**

*M.App.Fin, CA, B Ec*

Mr Sharman has been a member of the Board since 21 November 2005. Mr Sharman resigned from the Board on 29 February 2012. Mr Sharman has been involved with the Cyclopharm Group since early 2004 and resigned from his role as Managing Director of Cyclopharm on 3 June 2008. Mr Sharman served as a member of the Board Nominations Committees.

Mr Sharman has over 15 years experience in company management, private equity, investment banking and corporate finance. He has extensive experience in capital raisings, negotiation of key agreements, recovery and commercial strategies for performing and non-performing companies in all stages of company development. Mr Sharman is also a Non-Executive Director of Vita Life Sciences Limited (listed on the ASX).

Mr Sharman lives in Melbourne and is 45 years old.

#### **Mr A D H Beard – Non Executive Director (Independent)**

*B.Com, FCA*

Mr Beard was appointed to the Cyclopharm Board as a casual director on 28 April 2011.

Mr Beard is currently the Chief Executive Officer of CVC Limited, a position he has held since 2001. During the past three years, Mr Beard has also served as chairman of Cellnet Group Limited and director of the following listed companies: MNet Group Limited, Blue Energy Limited, Amadeus Energy Limited, Villa World Group and CVC Property Managers Limited.

Mr Beard resigned from the Board on 26 July 2011.

#### **Mr J M McBrayer – Company Secretary**

Mr McBrayer was appointed as Company Secretary on 25 March 2011 following the resignation of the previous company secretary, Mr William Richardson.

# Directors' Report

## Continued

### Interests in the shares of the Company and related bodies corporate

The movement during the reporting period in the number of ordinary Cyclopharm shares (no options are on issue) held directly, indirectly or beneficially, by Directors and key management personnel, including their personally-related entities is as follows:

|                                 | Interest | 31 December 2010<br>No. of shares | Shares<br>purchased<br>under<br>renounceable<br>Rights Issue<br>No. of shares | Off market<br>purchases<br>No. of shares | Off market sales<br>No. of shares | 31 December 2011<br>No. of shares |
|---------------------------------|----------|-----------------------------------|-------------------------------------------------------------------------------|------------------------------------------|-----------------------------------|-----------------------------------|
| <b>Directors</b>                |          |                                   |                                                                               |                                          |                                   |                                   |
| Mr VR Gould                     | NBI      | 2,848,092                         | 1,146,908                                                                     | -                                        | -                                 | 3,995,000                         |
| Mr DJ Heaney                    | BI       | 261,704                           | 81,783                                                                        | -                                        | -                                 | 343,487                           |
| Mr JS McBrayer                  | BI       | 859,090                           |                                                                               | -                                        | -                                 | 859,090                           |
| Mr JS McBrayer                  | NBI      | 300,000                           |                                                                               | -                                        | -                                 | 300,000                           |
| Mr JS Sharman                   | BI       | 1,410,000                         |                                                                               | -                                        | (400,000)                         | 1,010,000                         |
| Mr JS Sharman*                  | NBI      | 34,977                            |                                                                               | -                                        | -                                 | 34,977                            |
|                                 |          | 5,713,863                         | 1,228,691                                                                     | -                                        | (400,000)                         | 6,542,554                         |
| <b>Key Management Personnel</b> |          |                                   |                                                                               |                                          |                                   |                                   |
| Prof N Morcos                   | BI       | 58,297                            | -                                                                             | 1,000,000                                | -                                 | 1,058,297                         |
| Mr C Buttigieg                  | NBI      | 100,000                           | -                                                                             | -                                        | (100,000)                         | -                                 |
|                                 |          | 158,297                           | -                                                                             | 1,000,000                                | (100,000)                         | 1,058,297                         |

NBI: Non beneficial interests

BI: Beneficial interest

\*Mr Sharman resigned on 29 February 2012.

### DIVIDENDS

No dividends were declared or paid during the financial year.

The balance of franking credit available for future dividend payments is nil.

### PRINCIPAL ACTIVITIES

During the year the principal continuing activities of the consolidated entity consisted of the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development.

### OPERATING AND FINANCIAL REVIEW

#### Operating Results for the Year

For the financial year, the economic entity incurred a consolidated loss after tax attributable to members of \$956,220 (2010: profit after tax of \$450,106).

# Directors' Report

## Continued

### Financial Position

Net assets have increased from \$13,766,154 as at 31 December 2010 to \$14,604,799 as at 31 December 2011 predominantly due to net proceeds of \$1,976,284 received from the capital raising exercise noted below. This was offset by the net loss of \$956,220 for the year and a deterioration of \$189,469 in the foreign currency translation reserve.

### SIGNIFICANT CHANGES IN STATE OF AFFAIRS

#### Shares issued during the year

On 8 December 2011, the Company completed a capital raising exercise comprising a pro-rata renounceable entitlement offer to eligible shareholders of 1 share for every 3.2 shares held by eligible shareholders at an issue price of \$0.04 per rights share resulting in the issue of 52,566,802 shares, raising \$2,102,672 before share issue costs of \$126,388.

#### Banking Facilities

The National Australia Bank renewed the funding of Cyclopharm's debt facility with a flexible rate loan which expires in December 2015. The facility is secured by a first registered mortgage debenture over Cyclopharm Limited and a guarantee and indemnity from Cyclomedica Australia Pty Ltd, CycloPET Pty Ltd, Allrad No. 28 Pty Ltd and Allrad No. 29 Pty Ltd. The National Australia Bank has a registered Fixed and Floating Charge and First Registered Debenture charges over these companies.

The Group has breached one of its banking covenants during the year ended 31 December 2011, being an Event of Default triggered by variances greater than 15% of Actual Earnings Before Interest and Taxes (EBIT) as compared to Budgeted EBIT. The bank has agreed not to take action at this point in time.

### SIGNIFICANT EVENTS AFTER BALANCE DATE

No matters or circumstances have arisen since the end of the financial year, not otherwise dealt with in the financial report, which significantly affected or may significantly affect the operations of the Group, financial position or the state of affairs of the Group in future financial periods.

### LIKELY DEVELOPMENTS AND FUTURE RESULTS

#### Technegas

As the USA represents such a major growth opportunity, your Directors will continue to sensibly pursue entry into this market. Patient recruitment is anticipated to start in the second quarter of 2012.

#### Molecular Imaging

Management will focus on securing new customers to purchase the PET radiopharmaceuticals.

### ENVIRONMENTAL REGULATIONS

Cyclopet Pty Limited, a member of the consolidated group's operations is subject to significant environmental regulations under the Radiation Control Act, 1990 by the Department of Environment, Climate Change and Water. The Board believe that the consolidated group has adequate systems in place for the management of its environmental requirements as they apply to the consolidated group.

# Directors' Report

## Continued

### RETIREMENT, ELECTION AND CONTINUATION IN OFFICE OF DIRECTORS

In accordance with the Company's Constitution all Directors have been elected by members at the Annual General Meeting (AGM) with the exception of Mr McBrayer. Mr McBrayer was appointed as Managing Director on 3 June 2008 and under the Constitution is exempt from election by members.

### INDEMNIFICATION AND INSURANCE OF OFFICERS

In accordance with clause 49.1 of Cyclopharm's constitution and section 199A of the Corporations Act 2001 the Company has resolved to indemnify its Directors and officers for a liability to a third party provided that:

1. the liability does not arise from conduct involving a lack of good faith; or
2. the liability is for costs and expenses incurred by the director or officer in defending proceedings save as not permitted by law.

During or since the financial year, the Company has paid premiums in respect of a contract insuring all the Directors against legal costs incurred in defending proceedings for conduct involving:

- a) a wilful breach of duty; or
- b) a contravention of sections 182 or 183 of the Corporations Act 2001, as permitted by section 199B of the Corporations Act 2001.

The total amount of insurance contract premiums paid for the year ending 31 December 2012 are \$15,941 (For the year ended 31 December 2011 \$15,818).

The Officers of the Company covered by the insurance policy include the Directors, the Company Secretary and Executive Officers. The indemnification of the Directors and officers will extend for a period of at least 6 years in relation to events taking place during their tenure (unless the Corporations Act 2001 otherwise precludes this time frame of protection.)

The liabilities insured include costs and expenses that may be brought against the Officers in their capacity as Officers of the Company that may be incurred in defending civil or criminal proceedings that may be brought against the Officers of the Company or a controlled entity.

### AUDITOR'S INDEPENDENCE DECLARATION

A copy of the Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 is set out on page 24.

Fees of \$25,526 (2010: \$12,077) have been paid for share registry services and fees of \$10,000 (2010: \$11,030) for taxation services to an associate of Russell Bedford NSW for the year ended 31 December 2011 for non-audit related services. The Board of Directors is satisfied that the provision of non-audit services during the year is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*. The nature and scope of each type of non-audit service does not compromise the general principles relating to auditor independence in accordance with APES 110: Code of Ethics for Professional Accountants set by the Accounting Professional and Ethical Standards Board.

The Company has not otherwise, during or since the financial year, indemnified or agreed to indemnify an auditor of the Company or any related body corporate.

# Directors' Report

## Continued

### REMUNERATION REPORT (AUDITED)

The Remuneration Report outlines the director and executive remuneration arrangements of the Company and the group in accordance with the requirements of the Corporations Act 2001 and its Regulations. It also provides the remuneration disclosures required by paragraphs Aus 25.4 to Aus 25.7.2 of AASB 124 Related Party Disclosures, which have been transferred to the Remuneration Report in accordance with Corporations Regulation 2M.6.04. For the purposes of this report Key Management Personnel of the group are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company and the group, directly or indirectly, including any director (whether executive or otherwise) of the parent Company, and includes the five executives in the parent and the group receiving the highest remuneration.

For the purposes of this report, the term 'executive' encompasses the Chief Executive, senior executives, general managers and secretaries of the parent and the group.

# Directors' Report

## Continued

| Consolidated                                 | Short-term employee benefits |                  |                             | Post employment benefits | Share-based payment | Total          | Performance related |
|----------------------------------------------|------------------------------|------------------|-----------------------------|--------------------------|---------------------|----------------|---------------------|
|                                              | Salary & Fees<br>\$          | Cash Bonus<br>\$ | Non-monetary benefits<br>\$ | Superannuation<br>\$     | \$                  | \$             | %                   |
| <b>2011</b>                                  |                              |                  |                             |                          |                     |                |                     |
| <b>Directors</b>                             |                              |                  |                             |                          |                     |                |                     |
| Vanda Gould<br>Non-Executive Director        | 41,200                       | -                | -                           | -                        | -                   | 41,200         | 0%                  |
| David Heaney<br>Non-Executive Director       | 30,900                       | -                | -                           | -                        | -                   | 30,900         | 0%                  |
| John Sharman *<br>Non-Executive Director     | 15,450                       | -                | -                           | -                        | -                   | 15,450         | 0%                  |
| Alexander Beard **<br>Non-Executive Director | -                            | -                | -                           | -                        | -                   | -              | 0%                  |
| <b>Executive Director</b>                    |                              |                  |                             |                          |                     |                |                     |
| James McBrayer<br>Managing Director          | 283,486                      | -                | -                           | 25,514                   | 8,050               | 317,050        | 3%                  |
| <b>Total Directors' Compensation</b>         | <b>371,036</b>               | <b>-</b>         | <b>-</b>                    | <b>25,514</b>            | <b>8,050</b>        | <b>404,600</b> | <b>2%</b>           |

\* Mr Sharman resigned on 29 February 2012.

\*\* Mr Beard was appointed on 28 April 2011 and resigned on 26 July 2011.

# Directors' Report

## Continued

|                                                              | Short-term employee benefits |                  |                             | Post employment benefits | Share-based payment | Total            | Performance related |
|--------------------------------------------------------------|------------------------------|------------------|-----------------------------|--------------------------|---------------------|------------------|---------------------|
|                                                              | Salary & Fees<br>\$          | Cash Bonus<br>\$ | Non-monetary benefits<br>\$ | Superannuation<br>\$     | \$                  | \$               | %                   |
| <b>Consolidated</b>                                          |                              |                  |                             |                          |                     |                  |                     |
| <b>2011</b>                                                  |                              |                  |                             |                          |                     |                  |                     |
| <b>Key Management Personnel</b>                              |                              |                  |                             |                          |                     |                  |                     |
| Nabil Morcos<br>Chief Operating Officer                      | 188,464                      | -                | -                           | 16,962                   | -                   | 205,426          | 0%                  |
| Gary Somerville<br>Quality and Regulatory Manager            | 118,420                      | -                | -                           | 10,657                   | -                   | 129,077          | 0%                  |
| Caryn Cheah *<br>Financial Controller                        | 36,826                       | -                | -                           | 3,314                    | -                   | 40,140           | 0%                  |
| Graham Phillips<br>Finance Manager                           | 112,694                      | -                | -                           | 10,142                   | -                   | 122,836          | 0%                  |
| Charles Buttigieg<br>Sales and Marketing Manager - Australia | 136,279                      | -                | -                           | 10,825                   | -                   | 147,104          | 0%                  |
| Bjorn Altmann<br>General Manager – Europe                    | 141,328                      | -                | -                           | -                        | -                   | 141,328          | 0%                  |
| Lynn McLauchlin<br>General Manager – Canada                  | 119,212                      | 27,464           | -                           | -                        | -                   | 146,676          | 19%                 |
| <b>Total Key Management Personnel's Compensation</b>         | <b>853,223</b>               | <b>27,464</b>    | <b>-</b>                    | <b>51,900</b>            | <b>-</b>            | <b>932,587</b>   | <b>3%</b>           |
| <b>Total Compensation</b>                                    | <b>1,224,259</b>             | <b>27,464</b>    | <b>-</b>                    | <b>77,414</b>            | <b>8,050</b>        | <b>1,337,187</b> | <b>3%</b>           |

\* Ms Cheah joined as Cyclopharm Limited's Financial Controller on 7 March 2011.

# Directors' Report

## Continued

|                                        | Short-term employee benefits |            |                       | Post employment benefits | Share-based payment | Total          | Performance related |
|----------------------------------------|------------------------------|------------|-----------------------|--------------------------|---------------------|----------------|---------------------|
|                                        | Salary & Fees                | Cash Bonus | Non-monetary benefits | Superannuation           |                     |                |                     |
| Consolidated                           | \$                           | \$         | \$                    | \$                       | \$                  | \$             | %                   |
| <b>2010</b>                            |                              |            |                       |                          |                     |                |                     |
| <b>Directors</b>                       |                              |            |                       |                          |                     |                |                     |
| Vanda Gould<br>Non-Executive Director  | 41,200                       | -          | -                     | -                        | -                   | <b>41,200</b>  | 0%                  |
| David Heaney<br>Non-Executive Director | 30,900                       | -          | -                     | -                        | -                   | <b>30,900</b>  | 0%                  |
| John Sharman<br>Non-Executive Director | 15,450                       | -          | -                     | -                        | -                   | <b>15,450</b>  | 0%                  |
| <b>Executive Director</b>              |                              |            |                       |                          |                     |                |                     |
| James McBrayer<br>Managing Director    | 282,798                      | -          | -                     | 28,844                   | 14,175              | <b>325,817</b> | 4%                  |
| <b>Total Directors' Compensation</b>   | <b>370,348</b>               | <b>-</b>   | <b>-</b>              | <b>28,844</b>            | <b>14,175</b>       | <b>413,367</b> | <b>3%</b>           |

# Directors' Report

## Continued

|                                                              | Short-term employee benefits |                  |                             | Post employment benefits | Share-based payment | Total            | Performance related |
|--------------------------------------------------------------|------------------------------|------------------|-----------------------------|--------------------------|---------------------|------------------|---------------------|
|                                                              | Salary & Fees<br>\$          | Cash Bonus<br>\$ | Non-monetary benefits<br>\$ | Superannuation<br>\$     | \$                  | \$               | %                   |
| <b>Consolidated</b>                                          |                              |                  |                             |                          |                     |                  |                     |
| <b>2010</b>                                                  |                              |                  |                             |                          |                     |                  |                     |
| <b>Key Management Personnel</b>                              |                              |                  |                             |                          |                     |                  |                     |
| Nabil Morcos<br>Chief Operating Officer                      | 184,244                      | -                | -                           | 18,382                   | 82,000              | <b>284,626</b>   | 29%                 |
| Gary Somerville<br>Quality and Regulatory Manager            | 115,768                      | -                | -                           | 10,869                   | -                   | <b>126,637</b>   | 0%                  |
| Graham Phillips<br>Finance Manager                           | 107,603                      | -                | -                           | 10,764                   | -                   | <b>118,367</b>   | 0%                  |
| Charles Buttigieg<br>Sales and Marketing Manager - Australia | 126,639                      | -                | -                           | 9,233                    | -                   | <b>135,872</b>   | 0%                  |
| Bjorn Altmann<br>General Manager – Europe                    | 152,644                      | -                | -                           | -                        | -                   | <b>152,644</b>   | 0%                  |
| Lynn McLauchlin<br>General Manager – Canada                  | 127,722                      | 28,500           | -                           | -                        | -                   | <b>156,222</b>   | 18%                 |
| <b>Total Key Management Personnel's Compensation</b>         | <b>814,620</b>               | <b>28,500</b>    | -                           | <b>49,248</b>            | <b>82,000</b>       | <b>974,368</b>   | <b>11%</b>          |
| <b>Total Compensation</b>                                    | <b>1,184,968</b>             | <b>28,500</b>    | -                           | <b>78,092</b>            | <b>96,175</b>       | <b>1,387,735</b> | <b>9%</b>           |

# Directors' Report

## Continued



### Remuneration committee

The Remuneration Committee currently comprises Mr Gould, Committee Chairman and Mr Heaney.

The Remuneration Committee is responsible for:

- reviewing and approving the remuneration of Directors and other senior executives; and
- reviewing the remuneration policies of the Company generally.

### Remuneration philosophy

The performance of the Company depends upon the quality of its Directors and executives. To prosper, the Company must attract, motivate and retain highly skilled Directors and executives.

To this end, the Company embodies the following principles in its remuneration framework:

- provide competitive rewards to attract high calibre executives;
- link executive rewards to shareholder value;
- have a significant portion of executive remuneration 'at risk'; and
- establish appropriate, demanding performance hurdles for variable executive remuneration.

### Remuneration structure

In accordance with best practice corporate governance, the structure of non-executive director and executive remuneration is separate and distinct.

### Non-executive director remuneration

#### Objective

The Board seeks to set aggregate remuneration at a level that provides the Company with the ability to attract and retain Directors of the highest calibre, whilst incurring a cost that is acceptable to Shareholders.

#### Structure

The Constitution and the ASX Listing Rules specify that the aggregate remuneration of non-executive Directors shall be determined from time to time by a general meeting. The latest determination was at the Annual General Meeting held in March 2007 when Shareholders approved an aggregate remuneration of \$100,000 per year.

The amount of aggregate remuneration sought to be approved by Shareholders and the fee structure is reviewed annually. The Board considers advice from external consultants as well as the fees paid to non-executive Directors of comparable companies when undertaking the annual review process.

Each director receives a fee as set out in the Director and Executive Remuneration Table for being a director of the Company. Directors' fees cover all main Board activities and the membership of committees. There are no additional fees for committee membership. These fees exclude any additional 'fee for service' based on arrangements with the Company, which may be agreed from time to time. Agreed out of pocket expenses are payable in addition to Directors' fees. There is no retirement or other long service benefits that accrue upon appointment to the Board. Retiring non-executive Directors are not currently entitled to receive a retirement allowance.



### Executive remuneration

#### Objective

The Company aims to reward executives with a level and mix of remuneration commensurate with their position and responsibilities within the Company so as to:

- reward executives for Company, business unit and individual performance against targets set by reference to appropriate benchmarks;
- align the interests of executives with those of Shareholders; and
- ensure total remuneration is competitive by market standards.

In determining the level and make-up of executive remuneration, the Remuneration Committee engages external consultants as needed to provide independent advice.

The Remuneration Committee has entered into a detailed contract of employment with the Managing Director and a standard contract with other executives. Details of these contracts are provided below.

Remuneration consists of the following key elements:

- Fixed remuneration (base salary, superannuation and non-monetary benefits)
- Variable remuneration
  - short term incentive (STI); and
  - long term incentive (LTI)

The proportion of fixed remuneration and variable remuneration (potential short term and long term incentives) for each executive is set out in the Director and Executive Remuneration Table.

### Fixed Remuneration

#### Objective

Fixed remuneration is reviewed annually by the Remuneration Committee. The process consists of a review of Company, business unit and individual performance, relevant comparative remuneration in the market and internally and, where appropriate, external advice on policies and practices. As noted above, the Committee has access to external advice independent of management.

#### Structure

Executives are given the opportunity to receive their fixed (primary) remuneration in a variety of forms including cash and fringe benefits. It is intended that the manner of payment chosen will be optimal for the recipient without creating undue cost for the Group. All forms of executive remuneration are detailed in the Remuneration Report.

### Variable remuneration - Short Term Incentive

The objective of the STI is to link the achievement of the Group's operational targets with remuneration received by the executives charged with meeting those targets. The total potential STI available is set at a level so as to provide sufficient incentive to the executive to achieve the operational targets and such that the cost to the Group is reasonable in the circumstances.

Actual STI payments granted to each executive depends on the extent to which specific targets set at the beginning of the year are met. The targets consist of a number of Key Performance Indicators (KPI's) covering both financial and non-financial, corporate and individual measures of performance. Typically included measures are sales, net profit after tax, customer service, risk management and leadership/team contribution. These measures were chosen as they represent the key drivers for short term success of the business and provide a framework for long term value.

# Directors' Report

## Continued



The Group has predetermined benchmarks that must be met in order to trigger payments under the STI scheme. On an annual basis, after consideration of performance against KPI's, the Remuneration Committee, in line with their responsibilities, determine the amount, if any, of the short term incentive to be paid to each executive. This process usually occurs within 3 months of reporting date.

The aggregate of annual STI payments available for executives across the Group is subject to the approval of the Remuneration Committee. Payments are delivered as a cash bonus in the following reporting period. Participation in the Short Term Incentive Plan is at the Directors discretion.

### **Variable remuneration – Long Term Incentive**

Long Term incentives are delivered under the Long Term Incentive Plan (LTIP), which is designed to reward sustainable, long-term performance in a transparent manner. Under the LTIP, individuals are granted LTIP shares, which have a two or three year performance period (Term). The number of LTIP Shares is determined by the Board. The number of LTIP shares that an individual will be entitled to at the end of the Term will depend on the extent to which the Hurdle has been met. Performance Hurdles are determined by the Board to align individual performance with the Company's performance.

At the Annual General Meeting held on 8 May 2007, Shareholders approved the Company's Long Term Incentive Plan ("Plan").

The purpose of the Plan is to encourage employees, Directors and officers to share in the ownership of the Company and therefore retain and motivate senior executives to drive performance at both the individual and corporate level. Performance hurdles have been determined by the Board to align individual performance with the Company's key success factors.

### **Employment contracts**

#### **Managing Director**

The Managing Director, Mr McBrayer, is employed under a rolling contract. Mr McBrayer's current contract was executed on 13 May 2008. Mr McBrayer's remuneration for 2011 and 2010 is disclosed in the tables on pages 16 and 18. Under the terms of the present contract:

- Each year from 1 January, on 31 December Mr McBrayer may be entitled to receive additional amounts up to a maximum of \$50,000 based on achieving certain benchmarks and targets.
- Mr McBrayer may resign from his position and thus terminate this contract by giving 6 months written notice unless a mutually agreeable date can be agreed upon.
- The Company may terminate this employment agreement by providing 6 months written notice or providing payment in lieu of the notice period.
- The Company may terminate the contract at any time without notice if serious misconduct has occurred. Where termination with cause occurs the Managing Director is only entitled to that portion of remuneration that is fixed, and only up to the date of termination.
- On 3 June 2008, two strictly limited recourse loans were made to Mr McBrayer under the Company's LTIP. The first loan was to enable the purchase of 700,000 shares for a period of 2 years at the price of 25 cents per share. These shares did not vest and lapsed in 2010. The second loan was to enable the purchase of 700,000 shares for a period of 4 years at the price of 35 cents per share.

#### **Other Executives (standard contracts)**

All executives have rolling contracts. The Company may terminate the executive's employment agreement by providing (depending on the individual's contract) between 1 to 3 months written notice or providing payment in lieu of the notice period. Where termination with cause occurs the executive is only entitled to that portion of remuneration that is fixed, and only up to the date of termination.

# Directors' Report

## Continued



### DIRECTORS' MEETINGS

The number of meetings of Directors (including meetings of committees of Directors) held during the year and the numbers of meetings attended by each director were as follows:

| Director         | Cyclopharm Board Meetings          |                          | Audit Committee Meetings           |                          | Board Nomination Committee         |                          | Remuneration Committee Meetings    |                          |
|------------------|------------------------------------|--------------------------|------------------------------------|--------------------------|------------------------------------|--------------------------|------------------------------------|--------------------------|
|                  | No. of Meetings Eligible to Attend | No. of Meetings Attended | No. of Meetings Eligible to Attend | No. of Meetings Attended | No. of Meetings Eligible to Attend | No. of Meetings Attended | No. of Meetings Eligible to Attend | No. of Meetings Attended |
| Mr V R Gould     | 10                                 | 10                       | 3                                  | 3                        | -                                  | -                        | 2                                  | 2                        |
| Mr J S Sharman   | 10                                 | 8                        | -                                  | -                        | -                                  | -                        | -                                  | -                        |
| Mr D J Heaney    | 10                                 | 10                       | 3                                  | 3                        | -                                  | -                        | 2                                  | 2                        |
| Mr J M McBrayer  | 10                                 | 10                       | -                                  | -                        | -                                  | -                        | -                                  | -                        |
| Mr A D H Beard * | 2                                  | 2                        | -                                  | -                        | -                                  | -                        | -                                  | -                        |

\* Mr Beard was appointed on 28 April 2011 and resigned on 26 July 2011.

### SHARE OPTIONS

There were no share options on issue as at year end.

### PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Company with leave of the Court under section 237 of the Corporations Act 2001.

This report is made and signed in accordance with a resolution of the Directors:

**James McBrayer**  
Managing Director and CEO

Sydney, 27 March 2012

# Auditor's Independence Declaration



**Russell Bedford**  
New South Wales

Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000  
Australia

T: **+61 2 9032 3050**  
F: +61 2 9032 3058  
E: [mail@russellbedfordnsw.com.au](mailto:mail@russellbedfordnsw.com.au)  
W: [www.russellbedford.com](http://www.russellbedford.com)

27 March 2012

The Board of Directors  
Cyclopharm Limited  
Building 75  
Business & Technology Park  
New Illawarra Road  
Lucas Heights NSW 2234

Dear Directors

## **AUDITORS INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001**

We declare that, to the best of our knowledge and belief, during the year ended 31 December 2011, there have been:

- No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
- No contraventions of any applicable Code of Professional Conduct in relation to the audit.

Yours faithfully

RUSSELL BEDFORD NSW  
Chartered Accountants

A handwritten signature in blue ink, appearing to be 'Wali Aziz', written over a blue circular stamp.

WALI AZIZ B.Com., C.A.  
Associate



Member of Russell Bedford International – with affiliated offices worldwide  
Liability limited by a scheme approved under Professional Standards Legislation

The Directors of Cyclopharm are responsible for the corporate governance of the Cyclopharm Group ("Cyclopharm" or the "Company"). The Board guides and monitors the business and affairs of the Company on behalf of the Shareholders by whom they are elected and to whom they are accountable.

The Company's main corporate governance practices are applicable to all subsidiaries and are summarised below.

## **1 Compliance with ASX best practice recommendations**

The ASX Listing Rules require a statement in a listed Company's Annual Report which discloses the extent to which the ASX 28 best practice recommendations have been followed in the reporting period. As a listed Company, Cyclopharm must identify those recommendations which have not been followed and provide reasons for non-compliance.

This Statement sets out in detail the Company's compliance with the ASX Corporate Governance Council's best practice recommendations.

The Company considers that practices comply with 26 of the ASX best practice recommendations as at 31 December 2011. The Company considers that its recommendations comply with the best practice recommendations, other than recommendations 4.2 and 8.3. Explanations for the departure are provided in this statement in section 3(a) and 5(a). A checklist summarising this is set out in section 8 of this Statement.

## **2 The Board of Directors**

### **(a) Membership**

The Board has a range of relevant financial and other skills, experience and expertise to meet its objectives. The current Board composition, including details of director backgrounds is contained within the Directors' Report.

*ASX Recommendation 2.6 (refer to best practice summary)*

The Company's Constitution requires a minimum of 3 Directors and a maximum of 9 Directors. As at 31 December 2011, there were three non-executive Directors and one executive director. The Chairman, Mr Gould, is a non-executive director.

The terms and conditions of appointment and retirement of Directors are set out in the Company's Constitution. The Board believes that its membership should have enough Directors to serve on various committees of the Board without overburdening the Directors or making it difficult for them to fully discharge their responsibilities.

### **(b) Board role and responsibilities**

The Board is responsible to Shareholders and investors for the Group's overall corporate governance.

The Board has established and approved a Board Charter. Under this Charter the Board is responsible for:

- Considering and approving the corporate strategies proposed by the Managing Director and monitoring their implementation;
- Approving, overseeing and monitoring financial and other reporting to Shareholders, investors, employees and other stakeholders of the Company;
- Ensuring that the Company has the appropriate human, financial and physical resources to execute its strategies;
- Appointing and monitoring the performance of, and removing the Managing Director;
- Ratifying the appointment, and where appropriate, the removal of the Chief Financial Officer (or equivalent) and / or Company Secretary;



- Reviewing the effectiveness of the Company's policies and procedures regarding risk management, including internal controls and accounting systems; and
- Ensuring appropriate governance structures are in place including standards of ethical behaviour and a culture of corporate and social responsibility.

*ASX Recommendations 1.1, 2.6 (refer to best practice summary)*

### **(c) Chairman**

The Chairman, satisfies the requirements for an Independent Chairman under ASX *Recommendations 2.1 and 2.2* as Mr Gould is a non-executive, and has approximately 1.8% of the Shares (*Recommendations* permit 5%). Mr Gould is the Chairman of CVC Limited, whose subsidiary Stinoc Pty Limited controls 19.76% of the Shares of Cyclopharm. Mr Gould has advised the Board that under the Corporations Act tests he does not control these Shares and therefore has not disclosed them as part of his director's interest. However, given Mr Gould's role as Chairman of CVC Limited and Cyclopharm Limited, Cyclopharm's Board has considered this matter and decided, Mr Gould abstaining from expressing a view, that the Mr Gould's role at CVC Limited does not affect the operation of the Company and that so long as Mr Gould continues to act as he has since his appointment to the Boards of various entities making up the Cyclopharm Group, there is no reason to treat his actions as otherwise than that of an independent, non executive.

The Chairman is elected by the full Board of Directors and is responsible for:

- Leadership of the Board;
- The efficient organisation and conduct of the Board's functions;
- The promotion of constructive and respectful relations between Board members and between the Board and management;
- Contributing to the briefing of Directors in relation to issues arising at Board meetings;
- Facilitating the effective contribution of all Directors; and
- Committing the time necessary to effectively discharge the role of the Chairman.

*ASX Recommendation 2.3 (refer to best practice summary)*

### **(d) Independent Directors**

The Company recognises that independent Directors are important in assuring Shareholders that the Board is properly fulfilling its role and is diligent in holding senior management accountable for its performance. The Board assesses each of the Directors against specific criteria to decide whether they are in a position to exercise independent judgement.

Directors are considered to be independent if they are independent of management and free from any business or other relationship that could materially interfere with, the exercise of their unfettered and independent judgement. Materiality is assessed on a case-by-case basis by reference to each director's individual circumstances rather than general materiality thresholds.

In assessing independence, the Board considers whether the director has a business or other relationship with the Company, directly or as a partner, shareholder or officer of a Company or other entity that has an interest or a business relationship with the Company or another Cyclopharm group member.

Mr Heaney, Mr Gould and Mr Sharman (who has since resigned from the Board on 29 February 2012) meet the *Recommendations'* various tests of independence. Therefore, there is a majority of independent non-executive Directors and independent Directors on the Board.

*ASX Recommendation 2.1, 2.6 (refer to best practice summary)*

### **(e) Avoidance of conflicts of interest by a director**

In accordance with the Corporations Act and the Company's Constitution, Directors must keep the Board advised of any interest that could potentially conflict with those of the Company.

In the event that a conflict of interest may arise, involved Directors must withdraw from all deliberations concerning the matter. They are not permitted to exercise any influence over other Board members further when that matter is being considered the Director may not vote on that matter, in accordance with the *Corporations Act*.

### **(f) Board Meetings**

The Board regularly monitors the operational and financial performance of the Company and the economic entity against budget and other key financial risks. Appropriate risk management strategies are developed to mitigate all identified risks of the business.

The number of times the Board has formerly met and the number of meetings attended by Directors during the financial year are reported in the Directors' Report. The Board Charter dictates that the Board will hold 10 scheduled meetings each year and, other meetings may be held at short notice as required.

### **(g) Review of Board Performance**

The process for conducting the Board's annual performance review was agreed by the Board and was performed by the Chairman of the Board. Matters covered in the annual performance review include:

- The Board's contribution to developing strategy and policy;
- Interaction between the Board and management, and between Board members;
- The Board's processes to monitor business performance and compliance, control risk and evaluate Management;
- Board composition and structure; and
- The operation of the Board, including the conduct of Board meetings, Board Committee meetings and group behaviours.

*ASX Recommendation 2.5 (refer to best practice summary)*

### **(h) Nomination and appointment of new Directors**

Recommendations for nominations of new Directors are made by the Board Nominations Committee and considered by the Board in full. All current members of the Board are members of the Board Nominations Committee and Mr Gould is Chairman of the Committee. Board membership is reviewed annually by the Committee to ensure the Board has appropriate mix of qualifications, skills and experience. External advisers may be used in this process. Candidates are appointed by the Board and must stand for election at the next general meeting of Shareholders. If a new director is appointed during that year, that person will stand for election by Shareholders at the next annual general meeting. Shareholders are provided with relevant information on the candidates for election. The Nominations Committee reviews appointment criteria from time to time and makes recommendations concerning the re-election of any director by Shareholders.

*ASX Recommendations 2.1, 2.4 (refer to best practice summary)*

### **(i) Retirement and re-election of Directors**

The Company's Constitution states that one-third of Directors excluding the Managing Director must retire each year. The maximum term that each director can serve in any single term is three years. A director appointed during the year must, under the Constitution, retire at the next annual general meeting. At that meeting, they can stand for re-election. The Board Nominations Committee conducts a peer review of those Directors during the year in which that director will become eligible for re-election.

*ASX Recommendation 2.4 (refer to best practice summary)*

### (j) Board access to information and advice

All Directors have unrestricted access to Company records and information and receive regular detailed financial and operational reports from executive management to enable them to carry out their duties. Each Director has the right, subject to prior consultation with the Chairman, to seek independent professional advice at the Company's expense if such advice is essential to the proper discharge of the Director's duties. The Chairman may notify other Directors of the approach with any resulting advice being made available to all other Board members.

*ASX Recommendation 2.5 (refer to best practice summary)*

## 3 Board Committees

To assist the Board in fulfilling its duties and responsibilities, it has established the following committees:

- Audit and Risk Committee;
- Board Nominations Committee; and
- Remuneration Committee.

### (a) Audit and Risk Committee

The Audit and Risk Committee is governed by its charter, as approved by the Board. The Charter is available within the Corporate Governance section on Cyclopharm's website, at [www.cyclopharm.com.au](http://www.cyclopharm.com.au). The Audit and Risk Committee comprises two Directors, both being non-executive Directors. The non-executive Directors are Mr Gould, Chairman of the Audit Committee and Mr Heaney. The qualifications of the committee are located in the Directors' Report on pages 10 to 11. The Audit Committee's responsibilities include:

- Reviewing procedures, and monitoring and advising on the quality of financial reporting (including accounting policies and financial presentation);
- Reviewing the proposed fees, scope, performance and outcome of external audits. However, the auditors are appointed by the Board;
- Reviewing the procedures and practices that have been implemented by management regarding internal control systems;
- Ensuring that management have established and implemented a system for managing material financial and non-financial risks impacting the Company;
- Reviewing the corporate governance practices and policies of the Company; and
- Reviewing procedures and practices for protecting intellectual property ("IP") and aligning IP to strategy.

The Committee does not comply with the requirement to have an independent chairperson, who is not the chairperson of the Board. The Board believes that Mr Gould is the most appropriate person to be elected Chairman of the Committee. The Board does not comply with the ASX requirement to have at least 3 members on the Audit Committee. The Board believes that the experience that Mr Gould and Mr Heaney have in the finance industry adequately mitigates this non-compliance.

The number of times the Audit and Risk Committee has formerly met and the number of meetings attended by Directors during the financial year are reported in the Directors' Report.



The Audit and Risk Committee monitors and reviews:

- The effectiveness and appropriateness of the framework used by the Company for managing operational risk;
- The adequacy of the Company's internal controls including information systems controls and security;
- The adequacy of the process for reporting and responding to significant control and regulatory breaches;
- The effectiveness of the compliance function in ensuring adherence to applicable laws and regulations, including the actioning of legal and regulatory developments which may have a significant impact;
- Operational risk issues;
- Action plans to address control improvement areas.

The Company's Auditor, is requested to attend the Annual General Meeting and to be available to answer Shareholders questions about the conduct of the audit and the preparation and content of the Auditor's Report.

*ASX Recommendations 4.2, 4.3, 4.4, 4.5 (refer to best practice summary)*

### **(b) Board Nominations Committee**

The Board Nominations Committee is governed by its charter, as approved by the Board. The Charter is available within the Corporate Governance section on Cyclopharm's website, at [www.cyclopharm.com.au](http://www.cyclopharm.com.au).

The primary function of the Nominations Committee is performing review procedures to assist the Board in fulfilling its oversight responsibility to Shareholders by ensuring that the Board comprises individuals best able to discharge the responsibilities of Directors having regard to the law and the highest standards of governance. The Committee as delegated by the Board, is responsible for:

- developing and reviewing policies on Board composition, strategic function and size;
- performance review process of the Board, its Committees and individual Directors;
- developing and implementing induction programs for new Directors and ongoing education for existing Directors;
- developing eligibility criteria for nominating Directors;
- recommending appointment of Directors of the Board;
- reviewing director independence; and
- succession planning for the Board.

The number of times the Board Nominations Committee has formerly met and the number of meetings attended by Directors during the financial year are reported in the Directors' Report.

*ASX Recommendations 2.4, 2.6 (refer to best practice summary)*

### **(c) Remuneration Committee**

The Remuneration Committee is governed by its charter, as approved by the Board. The Charter is available within the Corporate Governance section on Cyclopharm's website, at [www.cyclopharm.com.au](http://www.cyclopharm.com.au).

The Remuneration Committee advises the Board on remuneration policies and practices generally, and makes specific recommendations on remuneration packages and other terms of employment for executive Directors, senior executives and non-executive Directors. Each member of the senior executive team signs a formal employment contract at the time of their appointment covering a range of matters including their duties, rights and responsibilities. Executive remuneration and other terms of employment are reviewed annually by the Committee having regard to personal and corporate performance contribution to long-term growth, relevant comparative information and independent expert advice. As well as base salary, remuneration packages may include superannuation and retirement and termination entitlements.

The Remuneration Report, which has been included in the Directors' Report, provides information on the Group's remuneration policies and payment details for Directors and key management personnel.

The number of times the Board Remuneration Committee has formerly met and the number of meetings attended by Directors during the financial year are reported in the Directors' Report.

*ASX Recommendation 9.2 (refer to best practice summary)*

#### **4 Recognising and managing risk**

A range of factors and risks some of which are beyond the Company's control can influence performance. The Company has in place a range of procedures to identify, assess and control risks which are reviewed by the Audit and Risk Committee and also by the Board periodically.

##### **(a) Board oversight of the risk management system**

The Board is responsible for approving and overseeing the risk management system. The Board reviews, at least annually, the effectiveness of the implementation of the risk management controls and procedures.

The Company recognises four main types of risk:

- Market risk, relates to the risk to earnings from changes in market conditions including economic activity, interest rates, investor sentiment and world events.
- Operational risk, relates to inadequacy of or a failure of internal processes, people or systems or from external events.
- Credit risk, relates to the risk that the other party to a transaction will not honour their obligation; and
- Regulatory risk, relates to the risk that there may be changes to legislation (including but not limited to laws which relate to corporations and taxation) in the future which restricts or limits in some way the Company's activities.

*ASX recommendations 7.1, 7.4 (refer to best practice summary)*

The Board, based on the recommendations of the Managing Director, Mr McBrayer, makes decisions on investments for the Company. The Board considers that the general retention by it of the power to make the final investment or divestment decision by majority vote provides an effective review of the investment strategy.

A majority of the Directors must approve any modification to the investment parameters applying to the Company's assets. Any proposed major change in investment strategy is first put to Shareholders for their approval.

The Board is also responsible for identifying and monitoring areas of significant business risk. Internal control measures currently adopted by the Board include:

- monthly reporting to the Board in respect of operations and the Company's financial position, with a comparison of actual results against budget; and
- regular reports to the Board by appropriate members of the management team and/or independent advisers, outlining the nature of particular risks and highlighting measures which are either in place or can be adopted to manage or mitigate those risks.

##### **(b) Risk management roles and responsibilities**

The Board is responsible for approving and reviewing the Company's risk management strategy and policy. Executive management is responsible for implementing the Board approved risk management strategy and developing policies, controls, processes and procedures to identify and manage risks in all of the Company's activities.

##### **(c) Managing Director and Chief Financial Officer Certification**

The Managing Director and Chief Financial Officer (or equivalent) provide to the Board written certification that in all material respects:



- The Company's financial statements present a true and fair view of the Company's financial condition and operational results and are in accordance with relevant accounting standards;
- The statement given to the Board on the integrity of the Company's financial statements is founded on a sound system of risk management, internal compliance and controls which implements the policies adopted by the Board; and
- The Company's risk management, internal compliance and control system is operating efficiently and effectively in all material respects.

*ASX recommendations 7.3 (refer to best practice summary)*

### **(d) Internal review and risk evaluation**

Assurance is provided to the Board by senior management on the adequacy and effectiveness of management controls for risk.

## **5 Remuneration**

### **(a) Overview**

The Remuneration Committee is responsible for reviewing the compensation arrangements for the Managing Director and other key personnel. The Remuneration Committee is also responsible for reviewing management incentive schemes, superannuation, retirement and termination entitlements, fringe benefits policies, and professional indemnity and liability insurance policies. The nature and amount of each element of the fee or salary of each director and each of the highest-paid officers of the Company are set out in the Remuneration Report on pages 16 to 19. Non-executive Directors' fees and payments are reviewed annually by the Board. Executive Directors are, subject to the information above, paid in salary or fees.

Mr Heaney and Mr Gould meet the Recommendation's various tests of independence. Therefore there is a majority of independent non-executive Directors on the Remuneration Committee and is chaired by an independent Director. The Board does not comply with the ASX requirement to have at least 3 members on the Remuneration Committee. The Board believes that the experience that Mr Gould and Mr Heaney have in the finance industry adequately mitigates this non-compliance.

*ASX recommendations 8.1, 8.2, 8.3, 8.4 (refer to best practice summary)*

### **(b) Equity-based key management personnel remuneration**

The Long Term Incentive Plan (LTIP) was approved by Shareholders at the Annual General Meeting held on 8 May 2007 in Melbourne. The purpose of the LTIP is to attract, retain and motivate employees and officers of the Company to drive performance at both the individual and corporate level. Any further participation by Directors in the LTIP will require Shareholders approval in accordance with the ASX Listing Rules.

## **6 Timely and balanced disclosure**

The Company believes that all Shareholders should have equal and timely access to material information about the Company including its financial situation, performance, ownership and governance. The Company's market disclosure policy approved by the Board and governs how the Company communicates with Shareholders and the market. Shareholders are encouraged to participate in general meetings.

### **(a) Market disclosure policy and practices**

The Continuous Disclosure and Market Communication Policy is available within the Corporate Governance section on Cyclopharm's website, at [www.cyclopharm.com.au](http://www.cyclopharm.com.au).

This policy includes provision for communications by the Company to:

- Be factual and subject to internal vetting and authorisation before issue;
- Be made in a timely manner;



- Not omit material information;
- Be expressed in a clear and objective manner to allow investors to assess the impact of the information when making investment decisions; and
- Be in compliance with ASX Listing Rules continuous disclosure requirements

The policy also contains guidelines on information that may be price sensitive. The Company Secretary has been nominated as the person responsible for communications with the Australian Securities Exchange (ASX). This role includes responsibility for ensuring compliance with the continuous disclosure requirements with the ASX Listing Rules and overseeing and coordinating information disclosure to the ASX.

*ASX Recommendations 5.1, 5.2, 6.1 (refer to best practice summary)*

### **(b) Communication strategy**

The Company publishes on its website the annual reports, profit announcements, press releases and notices to meeting to encourage shareholder and investor participation in Cyclopharm.

*ASX Recommendations 5.1, 6.1 (refer to best practice summary)*

## **7 Ethical and responsible decision-making**

### **(a) Code of Ethics and Conduct**

The Board endeavours to ensure that the Directors, officers and employees of Cyclopharm act with integrity and observe the highest standards of behaviour and business ethics in relation to their corporate activities. All officers and employees are expected to:

- comply with the law;
- act in the best interests of the Company;
- be responsible and accountable for their actions; and
- observe the ethical principles of fairness, honesty and truthfulness, including prompt disclosure of potential conflicts.

*ASX Recommendations 3.1, 3.2, 3.3, 10.1 (refer to best practice summary)*

### **(b) Policy concerning trading in Company securities**

On 19 February 2009, the Board resolved to adopt a new Policy concerning trading in Company securities. An executive, director or relevant employees ('employee') must not trade in any securities of the Company at any time when they are in possession of unpublished, price sensitive information in relation to those securities. An employee should not deal in securities of Cyclopharm without receiving clearance from a Committee comprised of the Managing Director and the Chairman (or in the absence of either of these two directors by any other director) who has ensured that there is no unpublished price sensitive information.

Generally, an employee must not be given clearance to deal in any securities of Cyclopharm during a prohibited period. A 'prohibited period' means:

- (a) The period from year end and preliminary announcement of the full year results (usually 1 February to end February);
- (b) The period from half year end and preliminary announcement of the half year results (usually 1 August to end August); and
- (c) Any other periods advised to employees by the Board (via the Company Secretary).

As required by the ASX Listing Rules, the Company notifies the ASX of any transaction conducted by directors in the securities of the Company.

# Corporate Governance

## Continued

### 8 Diversity

The Company publishes on its website its Diversity Policy.

The proportion of women employees within the following three levels as at 31 December 2011 are:

- |                              |     |
|------------------------------|-----|
| • Whole organisation         | 30% |
| • Senior executive positions | 18% |
| • Board                      | 0%  |

The Board has set the following objectives which are reviewed annually:

- Establish a Diversity Committee to oversee selection of new board members and senior executives;
- For vacancies at the Board and Senior Management level ensure that a diverse candidate pool and input from a diverse selection pool;
- Establish a senior mentoring program overseen by the Managing Director for all female senior managers.

*ASX Recommendations 3.2, 3.3 (refer to best practice summary)*



### 8 Checklist for summarising the best practice recommendations and compliance

| ASX Principle                                                                                                                                      | Reference          | Compliance    |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|
| <b>Principle 1: Lay solid foundations for management and oversight</b>                                                                             |                    |               |
| 1.1 Formalise and disclose the functions reserved to the board and those delegated to management                                                   | 2b                 | comply        |
| 1.2 Companies should disclose the process for evaluating the performance of senior executives.                                                     | 2g, 5a, 5b         | comply        |
| 1.3 Provide the information indicated in the Guide to reporting on Principle 1.                                                                    | 2a, 2b, 5a, 5b     | comply        |
| <b>Principle 2: Structure the board to add value</b>                                                                                               |                    |               |
| 2.1 A majority of the board should be independent directors.                                                                                       | 2a, 2d, 2h         | comply        |
| 2.2 The chair should be an independent director                                                                                                    | 2c                 | comply        |
| 2.3 The roles of chair and managing director should not be exercised by the same individual                                                        | 2a, 2c             | comply        |
| 2.4 The board should establish a nomination committee                                                                                              | 2h, 2i, 3b         | comply        |
| 2.5 Companies should disclose the process for evaluating the performance of the board, its committees and individual directors                     | 2g, 3c             | comply        |
| 2.6 Provide the information in the Guide to reporting on this Principle 2                                                                          | 2a, 2b, 2d, 2j, 3b | comply        |
| <b>Principle 3: Promote ethical and responsible decision-making</b>                                                                                |                    |               |
| 3.1 Companies should establish a code of conduct and disclose the code or a summary of the code as to:                                             | 7a                 | comply        |
| 3.1.1 the practices necessary to maintain confidence in the company's integrity                                                                    |                    |               |
| 3.1.2 the practices necessary to take into account their legal obligations and the reasonable expectations of their stakeholders                   |                    |               |
| 3.1.3 the responsibility and accountability of individuals for reporting and investigating reports of unethical practices                          |                    |               |
| 3.2 Disclose the policy concerning diversity including achieving gender diversity and the board's assessment of achieving its objectives annually. | 8                  | comply        |
| 3.3 Provide the information indicated in the Guide to reporting on Principle 3.                                                                    | 7a                 | comply        |
| <b>Principle 4: Safeguard integrity in financial reporting</b>                                                                                     |                    |               |
| 4.1 The board should establish an audit committee                                                                                                  | 3a                 | comply        |
| 4.2 The audit committee should be structured so that it:                                                                                           | 3a                 | do not comply |
| 4.2.1 consists only of non-executive directors                                                                                                     |                    |               |
| 4.2.2 consists of a majority of independent directors                                                                                              |                    |               |
| 4.2.3 is chaired by an independent chair, who is not the chair of the board                                                                        |                    |               |
| 4.2.4 has at least three members                                                                                                                   |                    |               |
| 4.3 The audit committee should have a formal charter.                                                                                              | 3a                 | comply        |
| 4.4 Provide the information in the Guide to reporting on this Principle 4                                                                          | 2a, 3a             | comply        |



### 8 Checklist for summarising the best practice recommendations and compliance (continued)

| ASX Principle                                                                                                                                                                                                                                                                                                                                                | Reference | Compliance    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------|
| <b>Principle 5: Make timely and balanced disclosure</b>                                                                                                                                                                                                                                                                                                      |           |               |
| 5.1 Establish written policies and procedures designed to ensure compliance with ASX Listing Rule disclosure requirements and to ensure accountability at a senior management level for that compliance                                                                                                                                                      | 6a        | comply        |
| 5.2 Provide the information in the Guide to reporting on this Principle 5                                                                                                                                                                                                                                                                                    | 6a        | comply        |
| <b>Principle 6: Respect the rights of shareholders</b>                                                                                                                                                                                                                                                                                                       |           |               |
| 6.1 Design and disclose a communications strategy to promote effective communication with shareholders and encourage participation at general meetings                                                                                                                                                                                                       | 6a, 6b    | comply        |
| 6.2 Provide the information indicated in the Guide to reporting on Principle 6.                                                                                                                                                                                                                                                                              | 3a        | comply        |
| <b>Principle 7: Recognise and manage risk</b>                                                                                                                                                                                                                                                                                                                |           |               |
| 7.1 The board or appropriate board committee should establish policies on risk oversight and management                                                                                                                                                                                                                                                      | 4a        | comply        |
| 7.2 The board should require management to design and implement the risk management and internal control system to manage the company's material business risks and report to it on whether those risks are being effectively managed and disclose that management has reported to it as to the effectiveness of the company's management of business risks. | 4a        | comply        |
| 7.3 The chief executive officer (or equivalent) and chief financial officer (or equivalent) should state to the board in writing that in accordance with section 295A of the Corporations Act:                                                                                                                                                               | 4c        | comply        |
| 7.3.1 the statement given in accordance with best practice recommendation 4.1 (the integrity of financial statements) is founded on a sound system of risk management and internal compliance and controls to implement the policies adopted by the board                                                                                                    |           |               |
| 7.3.2 the company's risk management and internal compliance and control system is operating efficiently and effectively in all material respects                                                                                                                                                                                                             |           |               |
| 7.4 Provide the information in the Guide to reporting on this Principle 7                                                                                                                                                                                                                                                                                    | 4a        | comply        |
| <b>Principle 8: Remunerate fairly and responsibly</b>                                                                                                                                                                                                                                                                                                        |           |               |
| 8.1 The board should establish a remuneration committee                                                                                                                                                                                                                                                                                                      | 3c, 5a    | comply        |
| 8.2 Clearly distinguish the structure of non-executive director's remuneration from that of executives                                                                                                                                                                                                                                                       | 5a        | comply        |
| 8.3 The remuneration committee should be structured so that it consists of a majority of independent directors, chaired by an independent director and have at least three members.                                                                                                                                                                          | 5a        | do not comply |
| 8.4 Provide the information in the Guide to reporting on this Principle 8                                                                                                                                                                                                                                                                                    | 5a        | comply        |

# Statement of Comprehensive Income

for the year ended 31 December 2011

|                                                                 |       | Consolidated       |                  |
|-----------------------------------------------------------------|-------|--------------------|------------------|
|                                                                 | Notes | 2011<br>\$         | 2010<br>\$       |
| <b>CONTINUING OPERATIONS</b>                                    |       |                    |                  |
| Sales revenue                                                   | 4     | 10,314,506         | 9,464,605        |
| Finance revenue                                                 |       | 17,302             | 68,972           |
| <b>Total revenue</b>                                            |       | <b>10,331,808</b>  | <b>9,533,577</b> |
| Cost of materials and manufacturing                             | 4a    | (3,127,650)        | (2,308,992)      |
| Employee benefits expense                                       | 4e    | (3,454,450)        | (2,957,231)      |
| Advertising and promotion expense                               |       | (240,716)          | (238,646)        |
| Depreciation and amortisation expense                           | 4c    | (669,608)          | (350,546)        |
| Freight and duty expense                                        |       | (343,330)          | (342,666)        |
| Research and development expense                                | 4d    | (37,324)           | (16,847)         |
| Administration expense                                          | 4f    | (2,023,861)        | (1,663,503)      |
| Other expenses                                                  | 4g    | (688,328)          | (337,067)        |
| Share of loss of associate                                      | 11    | (583,273)          | (311,372)        |
| <b>(Loss) / Profit before tax and finance costs</b>             |       | <b>(836,732)</b>   | <b>1,006,707</b> |
| Finance costs                                                   | 4b    | (355,237)          | (198,299)        |
| <b>(Loss) / Profit before income tax</b>                        |       | <b>(1,191,969)</b> | <b>808,408</b>   |
| Income tax benefit / (expense)                                  | 5     | 235,749            | (358,302)        |
| <b>Net (Loss) / Profit for the year</b>                         |       | <b>(956,220)</b>   | <b>450,106</b>   |
| <b>Other comprehensive income after income tax</b>              |       |                    |                  |
| Exchange differences on translating foreign controlled entities |       | (189,469)          | (708,770)        |
| <b>Total comprehensive (loss) / income for the year</b>         |       | <b>(1,145,689)</b> | <b>(258,664)</b> |
| Loss per share (cents per share)                                | 6     | <b>cents</b>       | <b>cents</b>     |
| -basic (loss) / earnings per share for continuing operations    |       | (0.55)             | 0.26             |
| -basic (loss) / earnings per share                              |       | (0.55)             | 0.26             |
| -diluted (loss) / earnings per share                            |       | (0.55)             | 0.26             |

The Statement of Comprehensive Income is to be read in conjunction with the notes to the financial statements.

# Statement of Financial Position

as at 31 December 2011

**cyclopharm**  
Nuclear Medicine



|                                                   |    | Consolidated      |                   |
|---------------------------------------------------|----|-------------------|-------------------|
|                                                   |    | 2011              | 2010              |
|                                                   |    | \$                | \$                |
| Notes                                             |    |                   |                   |
| <b>Assets</b>                                     |    |                   |                   |
| <b>Current Assets</b>                             |    |                   |                   |
| Cash and cash equivalents                         | 7  | 2,043,814         | 1,541,644         |
| Trade and other receivables                       | 8  | 4,139,147         | 4,295,487         |
| Inventories                                       | 9  | 2,487,081         | 2,546,867         |
| Other assets                                      |    | 17,282            | 25,490            |
| <b>Total Current Assets</b>                       |    | <b>8,687,324</b>  | <b>8,409,488</b>  |
| <b>Non-current Assets</b>                         |    |                   |                   |
| Inventories                                       | 9  | -                 | 702,000           |
| Trade and other receivables                       | 8  | 80,087            | 161,500           |
| Property, plant and equipment                     | 10 | 9,717,488         | 10,059,528        |
| Investments accounted for using the equity method | 11 | -                 | 188,231           |
| Intangible assets                                 | 12 | 2,808,314         | 2,621,152         |
| <b>Total Non-current Assets</b>                   |    | <b>12,605,889</b> | <b>13,732,411</b> |
| <b>Total Assets</b>                               |    | <b>21,293,213</b> | <b>22,141,899</b> |
| <b>Liabilities</b>                                |    |                   |                   |
| <b>Current Liabilities</b>                        |    |                   |                   |
| Trade and other payables                          | 13 | 1,110,406         | 1,082,492         |
| Interest bearing loans and borrowings             | 14 | 4,803,156         | 6,078,300         |
| Provisions                                        | 15 | 645,716           | 499,283           |
| Tax liabilities                                   | 5  | 16,090            | 318,850           |
| <b>Total Current Liabilities</b>                  |    | <b>6,575,368</b>  | <b>7,978,925</b>  |
| <b>Non-current Liabilities</b>                    |    |                   |                   |
| Interest bearing loans and borrowings             | 14 | 21,297            | 24,453            |
| Provisions                                        | 15 | 64,410            | 27,710            |
| Deferred tax liabilities                          | 5  | 27,339            | 344,657           |
| <b>Total Non-current Liabilities</b>              |    | <b>113,046</b>    | <b>396,820</b>    |
| <b>Total Liabilities</b>                          |    | <b>6,688,414</b>  | <b>8,375,745</b>  |
| <b>Net Assets</b>                                 |    | <b>14,604,799</b> | <b>13,766,154</b> |
| <b>Equity</b>                                     |    |                   |                   |
| Contributed equity                                | 16 | 13,065,192        | 11,088,908        |
| Employee equity benefits reserve                  |    | 322,199           | 314,149           |
| Foreign currency translation reserve              |    | (1,732,693)       | (1,543,224)       |
| Retained profits                                  |    | 2,950,101         | 3,906,321         |
| <b>Total Equity</b>                               |    | <b>14,604,799</b> | <b>13,766,154</b> |

The Statement of Financial Position is to be read in conjunction with the notes to the financial statements.

# Statement of Cash Flows

for the year ended 31 December 2011



|                                                                                  |       | Consolidated     |                    |
|----------------------------------------------------------------------------------|-------|------------------|--------------------|
|                                                                                  | Notes | 2011<br>\$       | 2010<br>\$         |
| <b>Operating activities</b>                                                      |       |                  |                    |
| Receipts from customers                                                          |       | 10,278,837       | 9,458,224          |
| Payments to suppliers and employees                                              |       | (8,992,946)      | (9,183,719)        |
| Interest received                                                                |       | 17,302           | 68,972             |
| Borrowing costs paid                                                             |       | (355,237)        | (198,299)          |
| Income tax paid                                                                  |       | (384,329)        | (236,138)          |
| <b>Net cash flows from / (used in) operating activities</b>                      | 7     | <b>563,627</b>   | <b>(90,960)</b>    |
| <b>Investing activities</b>                                                      |       |                  |                    |
| Investment in associate                                                          |       | (400,000)        | (500,000)          |
| Purchase of property, plant and equipment                                        |       | (276,040)        | (5,470,211)        |
| Receipts from deposit refunded                                                   |       | 161,500          | -                  |
| Payments for deferred expenditure                                                |       | (238,690)        | (247,897)          |
| <b>Net cash flows (used in) investing activities</b>                             |       | <b>(753,230)</b> | <b>(6,218,108)</b> |
| <b>Financing activities</b>                                                      |       |                  |                    |
| Proceeds from issue of shares                                                    |       | 2,102,672        | -                  |
| Costs of raising capital                                                         |       | (126,388)        | -                  |
| Proceeds from borrowings                                                         |       | -                | 3,743,603          |
| Repayment of borrowings                                                          |       | (1,278,300)      | (374,100)          |
| Loans from related entities                                                      |       | 400,000          | -                  |
| Loans to / (repaid) related entities                                             |       | (400,000)        | -                  |
| <b>Net cash flows from financing activities</b>                                  |       | <b>697,984</b>   | <b>3,369,503</b>   |
| <b>Net increase / (decrease) in cash and cash equivalents</b>                    |       | <b>508,381</b>   | <b>(2,939,565)</b> |
| <b>Cash and cash equivalents</b>                                                 |       |                  |                    |
| - at beginning of the period                                                     |       | <b>1,541,644</b> | <b>4,612,205</b>   |
| - net foreign exchange differences from translation of cash and cash equivalents |       | (6,211)          | (130,996)          |
| <b>- at end of the year</b>                                                      | 7     | <b>2,043,814</b> | <b>1,541,644</b>   |

The Statement of Cash Flows is to be read in conjunction with the notes to the financial statements.

# Statement of Changes in Equity

for the year ended 31 December 2011

|                                                           | Contributed<br>Equity<br>\$ | Other<br>Contributed<br>Equity<br>\$ | Total Contributed<br>Equity<br>\$ | Retained<br>Earnings<br>\$ | Foreign<br>Currency<br>Translation<br>Reserve<br>\$ | Employee<br>Equity<br>Benefits<br>Reserve<br>\$ | Total<br>\$        |
|-----------------------------------------------------------|-----------------------------|--------------------------------------|-----------------------------------|----------------------------|-----------------------------------------------------|-------------------------------------------------|--------------------|
| <b>CONSOLIDATED</b>                                       |                             |                                      |                                   |                            |                                                     |                                                 |                    |
| <b>Balance at<br/>1 January 2010</b>                      | <b>16,422,066</b>           | <b>(5,333,158)</b>                   | <b>11,088,908</b>                 | <b>3,456,215</b>           | <b>(834,454)</b>                                    | <b>217,972</b>                                  | <b>13,928,641</b>  |
| Profit for the year                                       | -                           | -                                    | -                                 | 450,106                    | -                                                   | -                                               | 450,106            |
| Other comprehensive income                                | -                           | -                                    | -                                 | -                          | (708,770)                                           | -                                               | (708,770)          |
| <b>Total comprehensive loss for the year</b>              | <b>-</b>                    | <b>-</b>                             | <b>-</b>                          | <b>450,106</b>             | <b>(708,770)</b>                                    | <b>-</b>                                        | <b>(258,664)</b>   |
| Cost of share based payments                              | -                           | -                                    | -                                 | -                          | -                                                   | 96,177                                          | 96,177             |
| <b>Total transactions with owners and other transfers</b> | <b>-</b>                    | <b>-</b>                             | <b>-</b>                          | <b>-</b>                   | <b>-</b>                                            | <b>96,177</b>                                   | <b>96,177</b>      |
| <b>Balance at<br/>31 December 2010</b>                    | <b>16,422,066</b>           | <b>(5,333,158)</b>                   | <b>11,088,908</b>                 | <b>3,906,321</b>           | <b>(1,543,224)</b>                                  | <b>314,149</b>                                  | <b>13,766,154</b>  |
| <b>Balance at<br/>1 January 2011</b>                      | <b>16,422,066</b>           | <b>(5,333,158)</b>                   | <b>11,088,908</b>                 | <b>3,906,321</b>           | <b>(1,543,224)</b>                                  | <b>314,149</b>                                  | <b>13,766,154</b>  |
| Loss for the year                                         | -                           | -                                    | -                                 | (956,220)                  | -                                                   | -                                               | (956,220)          |
| Other comprehensive income                                | -                           | -                                    | -                                 | -                          | (189,469)                                           | -                                               | (189,469)          |
| <b>Total comprehensive loss for the year</b>              | <b>-</b>                    | <b>-</b>                             | <b>-</b>                          | <b>(956,220)</b>           | <b>(189,469)</b>                                    | <b>-</b>                                        | <b>(1,145,689)</b> |
| Issue of renounceable rights shares                       | 2,102,672                   | -                                    | 2,102,672                         | -                          | -                                                   | -                                               | 2,102,672          |
| Cost of raising capital                                   | (126,388)                   | -                                    | (126,388)                         | -                          | -                                                   | -                                               | (126,388)          |
| Cost of share based payments                              | -                           | -                                    | -                                 | -                          | -                                                   | 8,050                                           | 8,050              |
| <b>Total transactions with owners and other transfers</b> | <b>1,976,284</b>            | <b>-</b>                             | <b>1,976,284</b>                  | <b>-</b>                   | <b>-</b>                                            | <b>8,050</b>                                    | <b>1,984,334</b>   |
| <b>Balance at<br/>31 December 2011</b>                    | <b>18,398,350</b>           | <b>(5,333,158)</b>                   | <b>13,065,192</b>                 | <b>2,950,101</b>           | <b>(1,732,693)</b>                                  | <b>322,199</b>                                  | <b>14,604,799</b>  |

The Statement of Changes in Equity is to be read in conjunction with the notes to the financial statements.

# Notes

for the year ended 31 December 2011



## 1. CORPORATE INFORMATION

The financial report of Cyclopharm Limited ("Cyclopharm" or the Company") for the year ended 31 December 2011 was authorised for issue by a resolution of the Directors as at the date of this report.

Cyclopharm is a Company limited by shares incorporated and domiciled in Australia. The shares are publicly traded on the Australian Securities Exchange ("ASX") under the code "CYC".

During the year the principal continuing activities of the consolidated entity consisted of the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development.

## 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### a) Basis of Preparation

The financial report is a general purpose financial report, which has been prepared in accordance with the requirements of the Corporations Act 2001 and Australian Accounting Standards. The financial report has been prepared on a historical cost basis.

The financial report is presented in Australian dollars.

There are no changes to accounting policies applicable for the financial year ended 31 December 2011 for the consolidated entity.

### b) Going Concern

The consolidated entity incurred a loss after tax of \$956,220 for the year ended 31 December 2011 in addition to breaching a banking covenant as disclosed in Note 14. The consolidated entity also expects to incur US\$250,000 on FDA clinical trials over the next 12 months (and US\$3.7m in total over the next 3 years).

These matters give rise to a material uncertainty that casts significant doubt upon the consolidated entity's ability to continue as a going concern. The ongoing operation is dependent upon:

- i) The consolidated entity achieving cash flow positive trading operations from its existing businesses
- ii) Continued financial support from its financiers

The directors have prepared cash flow projections that support the ability of the consolidated entity to continue as a going concern. These cash flow projections assume sales of \$2m from the Molecular Imaging business during the forecast period and continued financial support from its financiers. Therefore the directors are of the opinion that the consolidated entity can and will continue as a going concern. The directors have obtained a letter of support from the consolidated entity's key shareholder confirming their willingness to underwrite a future capital raising within the next twelve months if considered necessary.

In the event that the consolidated entity does not achieve positive cash flows from trading operations and continued financial support from its financiers it may not be able to continue operations as a going concern and therefore the consolidated entity may not be able to realise its assets and extinguish its liabilities in the ordinary course of operations and at the amounts stated in the financial statements.

No adjustments have been made to the recoverability and classification of recorded asset values and the amount and classification of liabilities that might be necessary should the consolidated entity and company not continue as going concerns.

### c) Statement of compliance

The financial report complies with Australian Accounting Standards, which include Australian equivalents to International Financial Reporting Standards ('AIFRS'). Compliance with AIFRS ensures that the financial report, comprising the financial statements and notes thereto, complies with International Financial Reporting Standards ('IFRS').

The following standards and amendments were available for early adoption but have not been applied by the consolidated entity in these financial statements:

#### **New Accounting Standards for Application in Future Periods**

The AASB has issued a number of new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods, some of which are relevant to the Group. The Group has decided not to early adopt any of the new and amended pronouncements. The Group's assessment of the new and amended pronouncements that are relevant to the Group but applicable in future reporting periods is set out below:

- AASB 9: Financial Instruments (December 2010) and AASB 2010–7: Amendments to Australian Accounting Standards arising from AASB 9 (December 2010) [AASB 1, 3, 4, 5, 7, 101, 102, 108, 112, 118, 120, 121, 127, 128, 131, 132, 136, 137, 139, 1023 & 1038 and Interpretations 2, 5, 10, 12, 19 & 127] (applicable for annual reporting periods commencing on or after 1 January 2013).

These Standards are applicable retrospectively and include revised requirements for the classification and measurement of financial instruments, as well as recognition and derecognition requirements for financial instruments.

The key changes made to accounting requirements include:

- simplifying the classifications of financial assets into those carried at amortised cost and those carried at fair value;
- simplifying the requirements for embedded derivatives;
- removing the tainting rules associated with held-to-maturity assets;
- removing the requirements to separate and fair value embedded derivatives for financial assets carried at amortised cost;
- allowing an irrevocable election on initial recognition to present gains and losses on investments in equity instruments that are not held for trading in other comprehensive income. Dividends in respect of these investments that are a return on investment can be recognised in profit or loss and there is no impairment or recycling on disposal of the instrument;
- requiring financial assets to be reclassified where there is a change in an entity's business model as they are initially classified based on: (a) the objective of the entity's business model for managing the financial assets; and (b) the characteristics of the contractual cash flows; and
- requiring an entity that chooses to measure a financial liability at fair value to present the portion of the change in its fair value due to changes in the entity's own credit risk in other comprehensive income, except when that would create an accounting mismatch. If such a mismatch would be created or enlarged, the entity is required to present all changes in fair value (including the effects of changes in the credit risk of the liability) in profit or loss.

The Group has not yet been able to reasonably estimate the impact of these pronouncements on its financial statements.

- AASB 2010–6: Amendments to Australian Accounting Standards – Disclosures on Transfers of Financial Assets [AASB 1 & AASB 7] (applicable for annual reporting periods beginning on or after 1 July 2011).



This Standard adds and amends disclosure requirements about transfers of financial assets, especially those in respect of the nature of the financial assets involved and the risks associated with them. Accordingly, this Standard makes amendments to AASB 1: First-time Adoption of Australian Accounting Standards, and AASB 7: Financial Instruments: Disclosures, establishing additional disclosure requirements in relation to transfers of financial assets.

This Standard will only affect certain disclosures relating to financial instruments and is not expected to significantly impact the Group.

- AASB 2010–8: Amendments to Australian Accounting Standards – Deferred Tax: Recovery of Underlying Assets [AASB 112] (applies to periods beginning on or after 1 January 2012).

This Standard makes amendments to AASB 112: Income Taxes and incorporates Interpretation 121 into AASB 112.

Under the current AASB 112, the measurement of deferred tax liabilities and deferred tax assets depends on whether an entity expects to recover an asset by using it or by selling it. The amendments introduce a presumption that an investment property is recovered entirely through sale. This presumption is rebutted if the investment property is held within a business model whose objective is to consume substantially all of the economic benefits embodied in the investment property over time, rather than through sale.

The amendments are not expected to significantly impact the Group.

- AASB 1054: Australian Additional Disclosures and AASB 2011–1: Amendments to Australian Accounting Standards arising from the Trans-Tasman Convergence Project [AASB 1, AASB 5, AASB 101, AASB 107, AASB 108, AASB 121, AASB 128, AASB 132 & AASB 134 and Interpretations 2, 112 & 113] (applicable for annual reporting periods commencing on or after 1 July 2011).

AASB 1054 sets out the Australian-specific disclosures that are additional to IFRS disclosure requirements.

The disclosure requirements in AASB 1054 were previously located in other Australian Accounting Standards.

These Standards are not expected to significantly impact the Group.

- AASB 10: Consolidated Financial Statements, AASB 11: Joint Arrangements, AASB 12: Disclosure of Interests in Other Entities, AASB 127: Separate Financial Statements (August 2011), AASB 128: Investments in Associates and Joint Ventures (August 2011) and AASB 2011–7: Amendments to Australian Accounting Standards arising from the Consolidation and Joint Arrangements Standards [AASB 1, 2, 3, 5, 7, 9, 2009–11, 101, 107, 112, 118, 121, 124, 132, 133, 136, 138, 139, 1023 & 1038 and Interpretations 5, 9, 16 & 17] (applicable for annual reporting periods commencing on or after 1 January 2013).

AASB 10 replaces parts of AASB 127: Consolidated and Separate Financial Statements (March 2008, as amended) and Interpretation 112: Consolidation – Special Purpose Entities. AASB 10 provides a revised definition of control and additional application guidance so that a single control model will apply to all investees. The Group has not yet been able to reasonably estimate the impact of this Standard on its financial statements.

AASB 11 replaces AASB 131: Interests in Joint Ventures (July 2004, as amended). AASB 11 requires joint arrangements to be classified as either “joint operations” (whereby the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities) or “joint ventures” (where the parties that have joint control of the arrangement have rights to the net assets of the arrangement). Joint ventures are required to adopt the equity method of accounting (proportionate consolidation is no longer allowed).

AASB 12 contains the disclosure requirements applicable to entities that hold an interest in a subsidiary, joint venture, joint operation or associate. AASB 12 also introduces the concept of a “structured entity”, replacing the “special purpose entity” concept currently used in Interpretation 112, and requires specific disclosures in respect of any investments in unconsolidated structured entities. This Standard will only affect disclosures and is not expected to significantly impact the Group.

To facilitate the application of AASBs 10, 11 and 12, revised versions of AASB 127 and AASB 128 have also been issued. These Standards are not expected to significantly impact the Group.

- AASB 13: Fair Value Measurement and AASB 2011–8: Amendments to Australian Accounting Standards arising from AASB 13 [AASB 1, 2, 3, 4, 5, 7, 9, 2009–11, 2010–7, 101, 102, 108, 110, 116, 117, 118, 119, 120, 121, 128, 131, 132, 133, 134, 136, 138, 139, 140, 141, 1004, 1023 & 1038 and Interpretations 2, 4, 12, 13, 14, 17, 19, 131 & 132] (applicable for annual reporting periods commencing on or after 1 January 2013).

AASB 13 defines fair value, sets out in a single Standard a framework for measuring fair value, and requires disclosures about fair value measurements.

AASB 13 requires:

- inputs to all fair value measurements to be categorised in accordance with a fair value hierarchy; and
- enhanced disclosures regarding all assets and liabilities (including, but not limited to, financial assets and financial liabilities) measured at fair value.

These Standards are not expected to significantly impact the Group.

- AASB 2011–9: Amendments to Australian Accounting Standards – Presentation of Items of Other Comprehensive Income [AASB 1, 5, 7, 101, 112, 120, 121, 132, 133, 134, 1039 & 1049] (applicable for annual reporting periods commencing on or after 1 July 2012).

The main change arising from this Standard is the requirement for entities to group items presented in other comprehensive income (OCI) on the basis of whether they are potentially reclassifiable to profit or loss subsequently.

This Standard affects presentation only and is not expected to significantly impact the Group.

- AASB 119: Employee Benefits (September 2011) and AASB 2011–10: Amendments to Australian Accounting Standards arising from AASB 119 [AASB 1, AASB 8, AASB 101, AASB 124, AASB 134, AASB 1049 & AASB 2011–8 and Interpretation 14] (applicable for annual reporting periods commencing on or after 1 January 2013).

These Standards introduce a number of changes to the presentation and disclosure of defined benefit plans, including:

- removal of the “corridor” approach from AASB 119, thereby requiring entities to recognise all changes in a net defined benefit liability (asset) when they occur;
- disaggregation of changes in a net defined benefit liability (asset) into service cost (including past service cost and gains and losses on non-routine settlements and curtailments), net interest expense (interest based on the net defined benefit liability (asset) using the discount rate applicable to post-employment benefits) and remeasurements (comprising actuarial gains and losses, return on plan assets less the “revenue” component of the net interest expense, and any change in the limit on a defined benefit asset). In addition, AASB 119 (September 2011) requires recognition of:
  - service cost and net interest expense in profit or loss; and
  - remeasurements in OCI; and
- introduction of enhanced disclosure requirements to facilitate the provision of more useful information in relation to an entity’s defined benefit plans.

AASB 119 (September 2011) also includes changes to the accounting for termination benefits that require an entity to recognise an obligation for such benefits at the earlier of:

- for an offer that may be withdrawn – when the employee accepts;
- for an offer that cannot be withdrawn – when the offer is communicated to affected employees; and
- where the termination is associated with a restructuring of activities under AASB 137: Provisions, Contingent Liabilities and Contingent Assets, and if earlier than the first two conditions – when the related restructuring costs are recognised.

The Group has not yet been able to reasonably estimate the impact of these changes on its financial statements.

### d) Basis of consolidation

The consolidated financial statements comprise the financial statements of Cyclopharm and its subsidiaries as at 31 December each year ('the Group').

#### **Subsidiaries**

Subsidiaries are consolidated from the date on which control is transferred to the Group and cease to be consolidated from the date on which control is transferred out of the Group. Where there is loss of control of a subsidiary, the consolidated financial statements include the results for the part of the reporting period during which Cyclopharm has control.

The financial statements of subsidiaries are prepared for the same reporting period as the parent Company, using consistent accounting policies. Adjustments are made to bring into line any dissimilar accounting policies that may exist.

#### **Transactions eliminated on consolidation**

All intercompany balances and transactions, including unrealised profits arising from intra-group transactions, have been eliminated in full. Unrealised losses are eliminated unless costs cannot be recovered.

For business combinations involving entities under common control, which are outside the scope of *AASB 3 Business Combinations*, the Company applies the purchase method of accounting by the legal parent.

#### **Business Combinations**

Business combinations occur where an acquirer obtains control over one or more businesses.

A business combination is accounted for by applying the acquisition method, unless it is a combination involving entities or businesses under common control. The business combination will be accounted for from the date that control is attained, whereby the fair value of the identifiable assets acquired and liabilities (including contingent liabilities) assumed is recognised (subject to certain limited exemptions).

When measuring the consideration transferred in the business combination, any asset or liability resulting from a contingent consideration arrangement is also included. Subsequent to initial recognition, contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability is remeasured each reporting period to fair value, recognising any change in fair value in profit or loss, unless the change in value can be identified as existing at acquisition date.

All transaction costs incurred in relation to the business combination are expensed to the statement of comprehensive income.

The acquisition of a business may result in the recognition of goodwill or a gain from a bargain purchase.

### e) Foreign currency translation

#### **Functional and presentation currency**

The functional currency of each of the group's entities is measured using the currency of the primary economic environment in which that entity operates. The consolidated financial statements are presented in Australian dollars (A \$) which is the parent entity's functional and presentation currency.

#### **Transactions and balances**

Transactions in foreign currencies are initially recorded in the functional currency at the exchange rates ruling at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items that are measured in terms of historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate when the fair value was determined.

Exchange differences arising on the translation of monetary items are recognised in the Statement of Comprehensive Income, except where deferred in equity as a qualifying cash flow hedge or net investment hedge. On disposal of a foreign entity the deferred cumulative amount in equity is recognised in the Statement of Comprehensive Income.

### **Group companies**

The functional currency of the overseas subsidiaries Cyclomedica Ireland Limited, Cyclomedica Germany GmbH, Cyclomedica Europe Limited, is European Euro (Euro €) and Cyclomedica Canada Limited is Canadian dollars (Can \$).

The financial results and position of foreign operations whose functional currency is different from the group's presentation currency are translated as follows:

- Assets and liabilities are translated at year-end exchange rates prevailing at that reporting date.
- Income and expenses are translated at the weighted average exchange rates for the period.
- Retained profits/equity are translated at the exchange rates prevailing at the date of the transaction.

Exchange differences arising on the translation of foreign operations are transferred directly to the group's foreign currency translation reserve in the Statement of Financial Position. These differences are recognised in the Statement of Comprehensive Income in the period in which the entity is disposed. Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in the Statement of Comprehensive Income.

### **f) Income tax**

Income tax on the profit and loss for the year comprises current and deferred tax. Income tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised directly to equity, in which case it is recognised in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially enacted at the Statement of Financial Position date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided using the Statement of Financial Position liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantially enacted at the Statement of Financial Position date and are expected to apply when the deferred tax asset is realised or the deferred tax liability is settled. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

### **Tax consolidation**

The Company is the head entity of the tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated group was 31 May 2006, Current tax expense/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "stand alone basis without adjusting for intercompany transactions" approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries is assumed by the head entity in the tax consolidated group and are recognised as amounts payable (receivable) to (from) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised.

Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

### g) Property, plant and equipment

Plant and equipment is measured at cost less accumulated depreciation and impairment losses.

The cost of fixed assets constructed within the economic entity includes the cost of materials, direct labour, borrowing costs and an appropriate proportion of fixed and variable overheads. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the Statement of Comprehensive Income during the financial period in which they are incurred.

Certain expenditure in establishing and commissioning Cyclopharm's PET central Pharmacies has been capitalised up to 31 December 2010. No impairment provision has been deemed appropriate. The Directors are satisfied that the future economic benefits will eventuate to justify the capitalisation of the expenditure incurred.

#### Impairment

The carrying amount of plant and equipment is reviewed annually by Directors to consider impairment. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the assets employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

#### Depreciation

The depreciable amount of all fixed assets including capitalised lease assets are depreciated on a straight-line basis over their useful lives commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset as follows:

|                                              | <b>Basis</b>                                         | <b>Method</b>                                                                                             |
|----------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Plant and equipment                          | 5 - 33%                                              | Straight-line method                                                                                      |
| Leasehold Improvements                       | 20 - 50%                                             | Straight-line method                                                                                      |
| Motor vehicles                               | 20 - 25%                                             | Straight-line method                                                                                      |
|                                              | <b>New Patents and licences</b>                      | <b>Technegas Development costs</b>                                                                        |
| Useful lives                                 | Patents - Finite<br>Licenses - Infinite              | Finite                                                                                                    |
| Method used                                  | 8 - 10 years - Straight line                         | 9 years - Straight line                                                                                   |
| Impairment test / Recoverable Amount testing | Annually and where an indicator of impairment exists | Amortisation method reviewed at each financial year-end;<br>Reviewed annually for indicator of impairment |



An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the item) is included in the Statement of Comprehensive Income in the year the item is derecognised.

### **h) Investments Accounted For Using The Equity Method**

Associates are companies in which the Group has significant influence through holding, directly or indirectly, 20% or more of the voting power of the Group. Investments in associates are accounted for in the financial statements by applying the equity method of accounting, whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the Group's share of net assets of the associate company. In addition, the Group's share of the profit or loss of the associate company is included in the Group's profit or loss.

The carrying amount of the investment includes goodwill relating to the associate. Any discount on acquisition whereby the Group's share of the net fair value of the associate exceeds the cost of investment is recognised in profit or loss in the period in which the investment is acquired.

Profit and losses resulting from transactions between the Group and the associate are eliminated to the extent of the Group's interest in the associate.

When the Group's share of losses in an associate equals or exceeds its interest in the associate, the Group discontinues recognising its share of further losses unless it has incurred legal or constructive obligations or made payments on behalf of the associate. When the associate subsequently makes profits, the Group will resume recognising its share of those profits once its share of the profits equals the share of the losses not recognised.

Details of the Group's investments in associates are provided in Note 11.

### **i) Borrowing costs**

Borrowing costs that are directly attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to prepare for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale, however capitalisation has ceased in December 2010 being when the Cyclopet asset was operational.

All other borrowing costs are recognised in the Statement of Comprehensive Income in the year in which they are incurred.

Borrowing costs include interest, amortisation of discounts or premiums relating to borrowings, amortisation of ancillary costs incurred in connection with arrangement of borrowings, foreign exchange losses net of hedged amounts on borrowings, including trade creditors and lease finance charges.

### **j) Intangibles**

#### **Intangible assets**

Intangible assets acquired separately are capitalised at cost and from a business combination are capitalised at fair value as at the date of acquisition. Following initial recognition, the cost model is applied to the class of intangible assets.

The useful lives of these intangible assets are assessed to be either finite or indefinite. Where amortisation is charged on assets with finite lives, this expense is taken to the Statement of Comprehensive Income through the 'depreciation and amortisation' line item.

Intangible assets, excluding development costs, created within the business are not capitalised and expenditure is charged against profits in the year in which the expenditure is incurred.



Intangible assets are tested for impairment where an indicator of impairment exists, and in the case of indefinite life intangibles, at each reporting date, either individually or at the cash generating unit level. Useful lives are also examined on an annual basis and adjustments, where applicable, are made on a prospective basis.

### **Research and development costs**

Expenditure on research activities is recognised as an expense when incurred.

Expenditure on development activities is capitalised only when it is probable that future benefits will exceed deferred costs and these benefits can be reliably measured. Capitalised development expenditure is stated at cost less accumulated amortisation. Amortisation is calculated using a straight-line method to allocate the costs over a period during which the related benefits are expected to be realised.

Expenditure on the development of the TechnegasPlus generator has been capitalised. A useful life of 9 years has been applied and amortisation for the year included in the Statement of Comprehensive Income. No impairment provision has been deemed appropriate. The Directors are satisfied that the future economic benefits will eventuate to justify the capitalisation of the expenditure incurred.

Expenditure on costs incurred in the application to the Food & Drug Administration authority have been capitalised. A useful life has not been determined as Cyclopharm have not yet received approval from the Food & Drug Administration authority. No impairment provision has been deemed necessary at balance date. The Directors are satisfied that the future economic benefits will eventuate to justify the carrying value of the capitalised expenditure.

Development expenditure is tested annually for impairment or more frequently if events or changes in circumstances indicate that it might be impaired. Capitalised development expenditure is measured at cost less any accumulated amortisation and impairment losses.

### **k) Inventories**

Inventories are valued at the lower of cost and net realisable value where net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Costs incurred in bringing each product to its present location and conditions are accounted for as follows:

- Raw materials: purchase cost on a first-in, first-out basis;
- Finished goods and work-in-progress: cost of direct materials and labour and an appropriate portion of manufacturing overheads based on normal operating capacity but excluding borrowing costs.

### **l) Trade and other receivables**

Trade receivables, which generally have 30-90 day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts. A specific estimate for doubtful debts is made when collection of the full amount is no longer probable. Bad debts are written off when identified.

### **m) Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand, deposits held at call with banks, short-term deposits with an original maturity of three months or less and bank overdrafts. For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

### **n) Trade and other payables**

Trade payables and other payables are carried at amortised cost and represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. Trade payables are normally settled within 30 to 60 days.

### **o) Interest-bearing loans and borrowings**

All loans and borrowings are initially recognised at cost, being the fair value of the consideration received net of issue costs associated with the borrowing. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest rate method. Amortised cost is calculated by taking into account any issue costs and any discount or premium on settlement. Gains and losses are recognised in the Statement of Comprehensive Income when the liabilities are derecognised and as well as through the amortisation process.

### **p) Provisions**

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of past events, for which it is probable that an outflow of economic benefits will result and that an outflow can be reliably measured. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the Statement of Comprehensive Income net of any reimbursement.

### **q) Employee entitlements**

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

Employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled plus related on-costs. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow (after applying probability) to be made in respect of services provided by employees up to the reporting date. In determining the present value of future cash outflows, the market yield as at the reporting date on national government bonds, which have terms to maturity approximating the terms of the related liability, are used.

Employee benefit expenses and revenues arising in respect of wages and salaries, non-monetary benefits, annual leave, long service leave and other leave benefits; and other types of employee benefits are recognised against profits on a net basis in their respective categories.

### **r) Employee share and performance share schemes**

The fair value of performance rights issued under the Cyclopharm Long Term Incentive Plan are recognised as a personnel expense over the vesting period with a corresponding increase in Employee Equity Benefits Reserve.

The fair value of performance the implied option attached to shares granted is determined using a pricing model that takes into account factors that include exercise price, the term of the performance option, the vesting and performance criteria, the share price at grant date and the expected price volatility of the underlying share. The fair value calculation excludes the impact of any non market vesting conditions. Non market vesting conditions are included in assumptions about the number of performance options that are expected to become exercisable. At each balance date, the entity revises its estimate of the number of performance rights that are expected to become exercisable. The personnel expense recognised each period takes into account the most recent estimate.

Shares issued under employee and executive share plans are held in trust until vesting date. Unvested shares held by the trust are consolidated into the group financial statements.

### s) Leases

#### Finance Leases

Leases of fixed assets where substantially all the risks and benefits incidental to the ownership of the asset but not the legal ownership that is transferred to entities in the consolidated group, are classified as finance leases.

Finance leases are capitalised by recognising an asset and a liability at the lower of the amounts equal to the fair value of the leased property or the present value of the minimum lease payments, including any guaranteed residual values. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Leased assets are depreciated on a straight-line basis over the shorter of their estimated useful lives or the lease term.

#### Operating Leases

Leases where the lessor retains substantially all the risks and benefits of ownership of the asset are classified as operating leases. Operating lease payments are recognised as an expense in the Statement of Comprehensive Income on a straight-line basis over the lease term. Lease incentives under operating leases are recognised as a liability and amortised on a straight-line basis over the life of the lease.

### t) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

#### Sale of goods

Revenue is recognised (net of returns, discounts and allowances) when the significant risks and rewards of ownership and therefore control of the goods have passed to the buyer and can be measured reliably. Control is considered to have passed to the buyer at the time of delivery of the goods to the customer.

#### Interest

Revenue is recognised as the interest accrues using the effective interest rate method, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument to the net carrying amount of the financial asset.

All revenue is stated net of the amount of goods and services tax ("GST").

### u) Other taxes

Revenues, expenses and assets are recognised net of the amount of GST except where the GST incurred is not recoverable from the Australian Taxation Office ("ATO"), and is therefore recognised as part of the asset's cost or as part of the expense item. Receivables and payables are stated inclusive of GST. The net amount of GST recoverable from, or payable to, the ATO is included as part of receivables or payables in the Statement of Financial Position. Cash flows are presented in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to the taxation authority are classified as operating cash flows.

### v) Financial instruments

Financial instruments are initially measured at cost on trade date, which includes transaction costs, when the related contractual rights or obligations exist. Subsequent to initial recognition these instruments are measured as set out below.

### **Financial assets at fair value through profit and loss**

A financial asset is classified in this category if acquired principally for the purpose of selling in the short term, or if so designated by management and within the requirement of AASB139: Recognition and Measurement of Financial Instruments.

### **Loans and receivables**

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method.

### **De-recognition of financial instruments**

#### **Financial assets**

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised when:

- the rights to receive cash flows from the asset have expired;
- the Group retains the right to receive cash flows from the asset, but has assumed an obligation to pay them in full without material delay to a third party under a 'pass-through' arrangement; or
- the Group has transferred its rights to receive cash flows from the asset and either (a) has transferred substantially all the risks and rewards of the asset, or (b) has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognised to the extent of the Group's continuing involvement in the asset. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration received that the Group could be required to repay.

#### **Financial liabilities**

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in profit or loss.

### **Impairment of financial assets**

The Group assesses at each Statement of Financial Position date whether a financial asset or group of financial assets is impaired.

#### **Financial assets carried at amortised cost**

If there is objective evidence that an impairment loss on loans and receivables carried at amortised cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). The carrying amount of the asset is reduced either directly or through use of an allowance account. The amount of the loss is recognised in profit or loss.



The Group first assesses whether objective evidence of impairment exists individually for financial assets that are individually significant, and individually or collectively for financial assets that are not individually significant. If it is determined that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, the asset is included in a group of financial assets with similar credit risk characteristics and that group of financial assets is collectively assessed for impairment. Assets that are individually assessed for impairment and for which an impairment loss is or continues to be recognised are not included in a collective assessment of impairment.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed. Any subsequent reversal of an impairment loss is recognised in profit or loss, to the extent that the carrying value of the asset does not exceed its amortised cost at the reversal date.

### **Financial assets carried at cost**

If there is objective evidence that an impairment loss has been incurred on an unquoted equity instrument that is not carried at fair value (because its fair value cannot be reliably measured), or on a derivative asset that is linked to and must be settled by delivery of such an unquoted equity instrument, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the current market rate of return for a similar financial asset.

## **w) Contributed equity**

### **Share capital**

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

### **Other contributed equity**

In accordance with *UIG 1052 Tax Consolidation Accounting*, additional contributed equity was recorded to recognise the transfer of tax liabilities from Vita Medical Limited to Vita Life Sciences Limited, being the parent of the Australian tax consolidated group at the relevant time. This event occurred prior to Cyclopharm acquiring its interests in the net assets of Vita Medical Limited.

As part of the restructure a subsidiary of Cyclopharm, Vita Medical Australia Pty Ltd acquired all the assets, liabilities and business from Vita Medical Limited, the former group parent.

With effect from 31 May 2006, Cyclopharm also acquired 100% of the other group operating subsidiaries from the ultimate holding company, Vita Life Sciences Limited. Accordingly, the group comprises Cyclopharm and the following wholly owned subsidiaries:

- Cyclomedica Australia Pty Ltd (formerly Vita Medical Australia Pty Ltd)
- Cyclomedica Ireland Ltd (formerly Vitamedica Europe Ltd)
- Cyclomedica Europe Ltd
- Cyclomedica Canada Limited (formerly Vita Medical Canada Ltd)
- Cyclomedica Germany GmbH
- Allrad 28 Pty Ltd
- Allrad 29 Pty Ltd

These entities collectively comprise the medical diagnostic equipment and associated consumables business formerly operated as the Vita Medical Group – now known as the Cyclopharm Group. The transaction has been accounted for as a 'reverse acquisition' as defined in *AASB 3 Business Combinations* whereby Cyclopharm is the legal parent and Cyclomedica Australia Pty Limited is the financial parent, which for accounting purposes is deemed to be the acquirer.



The consideration for the minority interests of the controlled entities and costs of acquisition have been charged to other contributed equity in accordance with *AASB 127 Consolidated and Separate Financial Statements*.

### x) Earnings per share

#### Basic earnings per share

Basic earnings per share is determined by dividing the net profit/(loss) after income tax attributable to members of the Company by the weighted average number of ordinary shares outstanding during the financial year. Where a change in the number of ordinary shares on issue without a corresponding change in recognised resources during the year the number of ordinary shares for all periods presented are correspondingly adjusted as if the event had occurred at the beginning of the earliest period presented.

#### Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. Where a change in the number of ordinary shares on issue without a corresponding change in recognised resources during the year the number of ordinary shares for all periods presented are correspondingly adjusted as if the event had occurred at the beginning of the earliest period presented.

### y) Key Estimates and Judgments

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimate is revised and in any future years affected.

In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognised in the financial statements are described in the following notes:

- Note 2(b) Going Concern
- Note 12 - Intangible Assets
- Note 15 - Provisions
- Note 23 - Share Based Payment Plans

### 3. SEGMENT REPORTING

The Group's primary segment reporting format is business segments as the Group's risks and returns are affected predominantly by differences in the products and services produced. The Group's secondary segment is geographical.

The operating businesses are organised and managed separately according to the nature of the products and services provided, with each segment representing a strategic business unit that offers different products and serves different markets.

The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.

The Molecular Imaging segment will produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease.

Transfer prices between business segments are set on an arm's length basis in a manner similar to transactions with third parties. Segment revenue, segment expense and segment result include transfers between business segments. Those transfers are eliminated on consolidation.

### 3. SEGMENT REPORTING (continued)

#### Business segments

The tables under the heading business segments present revenue and profit information and certain asset and liability information regarding business segments for the years ended 31 December 2011 and 31 December 2010.

#### Geographical segments

The tables under the heading geographical segment present revenue and profit information and certain asset and liability information regarding geographical segments for the years ended 31 December 2011 and 31 December 2010.

#### Business Segments

| For the year ended<br>31 December 2011       | Consolidated     |                    | Total              |
|----------------------------------------------|------------------|--------------------|--------------------|
|                                              | Technegas        | Molecular Imaging  |                    |
|                                              | \$               | \$                 | \$                 |
| <b>Revenue</b>                               |                  |                    |                    |
| Sales to external customers                  | 9,465,455        | 849,051            | 10,314,506         |
| Finance revenue                              | 11,944           | 5,358              | 17,302             |
| <b>Total revenue</b>                         | <b>9,477,399</b> | <b>854,409</b>     | <b>10,331,808</b>  |
| <b>Result</b>                                |                  |                    |                    |
| (Loss) / Profit before tax and finance costs | 1,699,883        | (2,536,615)        | (836,732)          |
| Finance costs                                | (84,070)         | (271,167)          | (355,237)          |
| <b>Profit / (Loss) before income tax</b>     | <b>1,615,813</b> | <b>(2,807,782)</b> | <b>(1,191,969)</b> |
| Income tax benefit / (expense)               | 51,039           | 184,710            | 235,749            |
| <b>Profit / (Loss) after income tax</b>      | <b>1,666,852</b> | <b>(2,623,072)</b> | <b>(956,220)</b>   |
| <b>Assets and liabilities</b>                |                  |                    |                    |
| Segment assets                               | 9,507,753        | 11,785,460         | 21,293,213         |
| Segment asset increases for the period :     |                  |                    |                    |
| - capital expenditure                        | 137,927          | 172,691            | 310,618            |
| Included in segment assets are :             |                  |                    |                    |
| - equity accounted associate                 | -                | -                  | -                  |
| Segment liabilities                          | (1,621,025)      | (5,067,389)        | (6,688,414)        |
| <b>Other segment information</b>             |                  |                    |                    |
| Depreciation and amortisation                | (248,835)        | (420,773)          | (669,608)          |
| Equity accounted (loss) of associate         | -                | (583,273)          | (583,273)          |

### 3. SEGMENT REPORTING (continued)

#### Business Segments (continued)

| For the year ended<br>31 December 2010              | Consolidated     |                   | Total            |
|-----------------------------------------------------|------------------|-------------------|------------------|
|                                                     | Technegas        | Molecular Imaging |                  |
|                                                     | \$               | \$                | \$               |
| <b>Revenue</b>                                      |                  |                   |                  |
| Sales to external customers                         | 9,442,763        | 21,842            | 9,464,605        |
| Finance revenue                                     | 63,802           | 5,170             | 68,972           |
| <b>Total revenue</b>                                | <b>9,506,565</b> | <b>27,012</b>     | <b>9,533,577</b> |
| <b>Result</b>                                       |                  |                   |                  |
| <b>Profit / (Loss) before tax and finance costs</b> | <b>1,845,650</b> | <b>(838,943)</b>  | <b>1,006,707</b> |
| Finance costs                                       | (172,857)        | (25,442)          | (198,299)        |
| <b>Profit / (Loss) before income tax</b>            | <b>1,672,793</b> | <b>(864,385)</b>  | <b>808,408</b>   |
| Income tax expense                                  | (358,302)        | -                 | (358,302)        |
| <b>Profit / (Loss) after income tax</b>             | <b>1,314,491</b> | <b>(864,385)</b>  | <b>450,106</b>   |
| <b>Assets and liabilities</b>                       |                  |                   |                  |
| Segment assets                                      | 10,603,331       | 11,538,568        | 22,141,899       |
| Segment asset increases for the period :            |                  |                   |                  |
| - capital expenditure                               | 56,182           | 9,871,046         | 9,927,228        |
| Included in segment assets are :                    |                  |                   |                  |
| - equity accounted associate                        | -                | 188,231           | 188,231          |
| Segment liabilities                                 | (3,152,832)      | (5,222,913)       | (8,375,745)      |
| <b>Other segment information</b>                    |                  |                   |                  |
| Depreciation and amortisation                       | (317,072)        | (33,474)          | (350,546)        |
| Equity accounted (loss) of associate                | -                | (311,372)         | (311,372)        |

### 3. SEGMENT REPORTING (continued)

#### Geographical Segments

| For the year ended           | Consolidated     |                  |                  |                | Total             |
|------------------------------|------------------|------------------|------------------|----------------|-------------------|
|                              | Asia Pacific     | Europe           | Canada           | Other          |                   |
| 31 December 2011             | \$               | \$               | \$               | \$             | \$                |
| <b>Revenue</b>               |                  |                  |                  |                |                   |
| Sales to external customers  | 3,009,527        | 5,490,202        | 1,695,289        | 119,488        | 10,314,506        |
| Finance revenue              | 16,216           | 1,086            | -                | -              | 17,302            |
| <b>Total segment revenue</b> | <b>3,025,743</b> | <b>5,491,288</b> | <b>1,695,289</b> | <b>119,488</b> | <b>10,331,808</b> |
| <b>Assets</b>                |                  |                  |                  |                |                   |
| Segment assets               | 16,178,810       | 4,232,612        | 881,791          | -              | 21,293,213        |

| For the year ended           | Consolidated     |                  |                  |               | Total            |
|------------------------------|------------------|------------------|------------------|---------------|------------------|
|                              | Asia Pacific     | Europe           | Canada           | Other         |                  |
| 31 December 2010             | \$               | \$               | \$               | \$            | \$               |
| <b>Revenue</b>               |                  |                  |                  |               |                  |
| Sales to external customers  | 2,280,115        | 5,487,463        | 1,598,679        | 98,348        | 9,464,605        |
| Finance revenue              | 59,832           | 9,140            | -                | -             | 68,972           |
| <b>Total segment revenue</b> | <b>2,339,947</b> | <b>5,496,603</b> | <b>1,598,679</b> | <b>98,348</b> | <b>9,533,577</b> |
| <b>Assets</b>                |                  |                  |                  |               |                  |
| Segment assets               | 17,282,538       | 4,075,722        | 783,639          | -             | 22,141,899       |



### 4. REVENUES AND EXPENSES

|                                               |                                                  | Consolidated |           |
|-----------------------------------------------|--------------------------------------------------|--------------|-----------|
|                                               |                                                  | 2011         | 2010      |
| Notes                                         |                                                  | \$           | \$        |
| <b>Revenue</b>                                |                                                  |              |           |
|                                               | Sales revenue                                    | 10,314,506   | 9,464,605 |
|                                               | Finance revenue                                  | 17,302       | 68,972    |
| <b>Expenses</b>                               |                                                  |              |           |
| <b>a) Cost of materials and manufacturing</b> |                                                  |              |           |
|                                               | Cost of materials and manufacturing              | 3,127,650    | 2,308,992 |
| <b>b) Finance costs</b>                       |                                                  |              |           |
|                                               | Interest paid on loans from external parties     | 355,237      | 198,299   |
| <b>c) Depreciation and amortisation</b>       |                                                  |              |           |
|                                               | Depreciation of plant and equipment              | 541,377      | 291,220   |
|                                               | Depreciation of leasehold improvements           | 76,703       | 10,914    |
|                                               | Amortisation of intangibles                      | 51,528       | 48,412    |
|                                               |                                                  | 669,608      | 350,546   |
| <b>d) Research &amp; development</b>          |                                                  |              |           |
|                                               | Research and development expense                 | 37,324       | 16,847    |
|                                               |                                                  | 37,324       | 16,847    |
| <b>e) Employee benefits expense</b>           |                                                  |              |           |
|                                               | Salaries and wages                               | 3,285,801    | 2,698,471 |
|                                               | Non-Executive Director fees and consultant costs | 160,599      | 162,583   |
|                                               | Share-based payments expense                     | 8,050        | 96,177    |
|                                               |                                                  | 3,454,450    | 2,957,231 |
| <b>f) Administration expense</b>              |                                                  |              |           |
|                                               | Legal and professional costs                     | 540,397      | 543,391   |
|                                               | Office and facility costs                        | 917,189      | 662,997   |
|                                               | Travel and motor vehicle costs                   | 566,275      | 457,115   |
|                                               |                                                  | 2,023,861    | 1,663,503 |
| <b>g) Other expenses</b>                      |                                                  |              |           |
|                                               | Realised Foreign exchange losses                 | 213,174      | 262,036   |
|                                               | Unrealised Foreign exchange (gains) / losses     | (6,072)      | 10,241    |
|                                               | Other                                            | 481,226      | 64,790    |
|                                               |                                                  | 688,328      | 337,067   |



### 5. INCOME TAX

#### The components of income tax expense comprise:

(a) Included in the income statement:

Current income tax (expense) / benefit

Deferred tax benefit / (expense)

(b) Taken directly to equity

Current income tax (expense) / benefit

Deferred tax benefit / (expense)

A reconciliation of income tax benefit / (expense) applicable to accounting (loss) / profit before income tax at the statutory income tax rate to income tax expense at the Group's effective income tax rate is as follows:

#### Accounting (loss) / profit before income tax

Statutory income tax rate of 30%

Expenditure not allowable for income tax purposes

Share based payments for which no deduction is obtained

Deferred expenditure

Effects of lower rates on overseas income

Tax losses not recognised in Australian tax group

Tax losses not recognised in foreign subsidiaries

#### Total income tax benefit / (expense)

Effective income tax rate

#### Current tax liabilities

Current income tax liability

#### Deferred tax assets/liabilities

Deferred tax assets and liabilities relate to the following:

Deferred tax assets from

Provisions

Share issue expenses (charged to equity)

Tax losses applied in current year

Tax losses of parent entity brought to account

Tax losses / (payable) transferred from Australian subsidiaries

Adjustment to recognise deferred tax asset arising from share issue costs

Investment accounted for using equity method

Transfer to deferred tax liability

#### Total deferred tax assets

Deferred tax liabilities from

Capitalised expenditure

Transfer from deferred tax assets

#### Total deferred tax liabilities

#### Unused tax losses for which no benefit has been recognised

as a deferred tax asset

#### Tax effect

Potential income tax benefit - at 30%

- at 28.25%

#### Consolidated

| 2011<br>\$         | 2010<br>\$       |
|--------------------|------------------|
| (81,569)           | (242,522)        |
| 317,318            | (115,780)        |
| <b>235,749</b>     | <b>(358,302)</b> |
| -                  | -                |
| 54,167             | -                |
| <b>54,167</b>      | <b>-</b>         |
| <b>(1,191,969)</b> | <b>808,408</b>   |
| 357,591            | (242,522)        |
| (1,728)            | (1,208)          |
| (2,415)            | (28,853)         |
| 76,034             | (146,089)        |
| 3,930              | 39,254           |
| (197,663)          | -                |
| -                  | 21,116           |
| <b>235,749</b>     | <b>(358,302)</b> |
| <b>(19.8%)</b>     | <b>(44.3%)</b>   |
| <b>16,090</b>      | <b>318,850</b>   |
| 551,350            | 223,418          |
| 54,167             | -                |
| -                  | (475,955)        |
| -                  | 413,273          |
| -                  | 62,682           |
| -                  | 48,389           |
| 268,394            | 93,412           |
| (873,911)          | (365,219)        |
| <b>-</b>           | <b>-</b>         |
| 901,250            | 709,876          |
| (873,911)          | (365,219)        |
| <b>27,339</b>      | <b>344,657</b>   |
| 1,187,030          | -                |
| 197,663            | -                |
| 194,204            | -                |
| <b>391,867</b>     | <b>-</b>         |

# Notes

## Continued

### 6. NET TANGIBLE ASSETS AND LOSS PER SHARE

#### Net Tangible Assets per share

|                                                                     | <b>Consolidated</b> |               |
|---------------------------------------------------------------------|---------------------|---------------|
|                                                                     | <b>2011</b>         | <b>2010</b>   |
|                                                                     | <b>\$</b>           | <b>\$</b>     |
| Net assets per share                                                | 0.08                | 0.08          |
| Net tangible assets per share                                       | 0.07                | 0.07          |
|                                                                     | <b>Number</b>       | <b>Number</b> |
| Weighted average number of ordinary shares for net assets per share | 174,469,063         | 171,012,616   |
|                                                                     | <b>2011</b>         | <b>2010</b>   |
|                                                                     | <b>\$</b>           | <b>\$</b>     |
| Net assets                                                          | 14,604,799          | 13,766,154    |
| Net tangible assets                                                 | 11,796,485          | 11,145,002    |

The weighted average number of ordinary shares includes the 52,566,802 shares issued in December 2011 in connection with the capital raising exercise.

#### Loss per share

|                                                                                              | <b>Consolidated</b> |               |
|----------------------------------------------------------------------------------------------|---------------------|---------------|
|                                                                                              | <b>2011</b>         | <b>2010</b>   |
|                                                                                              | <b>cents</b>        | <b>cents</b>  |
| Basic (loss) / earnings per share for continuing operations                                  | (0.55)              | 0.26          |
| Basic (loss) / earnings per share                                                            | (0.55)              | 0.26          |
| Diluted (loss) / earnings per share                                                          | (0.55)              | 0.26          |
|                                                                                              | <b>Number</b>       | <b>Number</b> |
| Weighted average number of ordinary shares for basic and diluted (loss) / earnings per share | 174,469,063         | 171,012,616   |
|                                                                                              | <b>2011</b>         | <b>2011</b>   |
|                                                                                              | <b>\$</b>           | <b>\$</b>     |
| (Loss) / Earnings used to calculate basic earnings per share                                 | (956,220)           | 450,106       |
| (Loss) / Earnings used to calculate diluted earnings per share                               | (956,220)           | 450,106       |

The weighted average number of ordinary shares includes the 52,566,802 shares issued in December 2011 in connection with the capital raising exercise.



## 7. CASH AND CASH EQUIVALENTS

|                                        | Consolidated     |                  |
|----------------------------------------|------------------|------------------|
|                                        | 2011             | 2010             |
|                                        | \$               | \$               |
| Cash at bank and in hand               | 2,043,814        | 1,541,644        |
| <b>Total cash and cash equivalents</b> | <b>2,043,814</b> | <b>1,541,644</b> |

Cash at bank and in hand earns interest at floating rates based on daily bank deposit rates.

The fair value of cash equivalents is \$2,043,814 (2010: \$1,541,644).

### Reconciliation of Statement of Cash Flows

For the purpose of the Statement of Cash Flows, cash and cash equivalents comprise the following:

|                          | 2011             | 2010             |
|--------------------------|------------------|------------------|
| Cash at bank and in hand | 2,043,814        | 1,541,644        |
|                          | <b>2,043,814</b> | <b>1,541,644</b> |

### (a) Reconciliation of net (loss) / profit after tax to net cash flows from operations

|                                                            |                  |                 |
|------------------------------------------------------------|------------------|-----------------|
| <b>Net (loss) / profit after tax</b>                       | <b>(956,220)</b> | <b>450,106</b>  |
| <b>Adjustments for non-cash income and expense items:</b>  |                  |                 |
| Depreciation                                               | 618,080          | 302,134         |
| Amortisation                                               | 51,528           | 48,412          |
| Share of loss in investment in associate                   | 588,231          | 311,769         |
| Movement provision for employee benefits                   | 183,133          | 64,078          |
| Movement in foreign exchange                               | (183,258)        | (577,774)       |
| Movement in employee benefits reserve                      | 8,050            | 96,177          |
| Movement in other provisions                               | 120,130          | (78,109)        |
|                                                            | <b>429,674</b>   | <b>616,793</b>  |
| <b>Increase/decrease in assets and liabilities:</b>        |                  |                 |
| (Increase) / decrease in receivables                       | (171,777)        | 71,626          |
| (Increase) / decrease in inventories                       | 761,787          | (5,875)         |
| (Increase) / decrease in other receivables                 | 136,108          | (78,007)        |
| Increase / (decrease) in creditors                         | 27,913           | (817,661)       |
| Increase / (decrease) in current tax liabilities           | (302,760)        | 144,811         |
| Increase / (decrease) in deferred tax liabilities          | (317,318)        | (22,647)        |
| <b>Net cash flow from / (used in) operating activities</b> | <b>563,627</b>   | <b>(90,960)</b> |



### 8. TRADE AND OTHER RECEIVABLES

|                                                  |              | <b>Consolidated</b> |                  |
|--------------------------------------------------|--------------|---------------------|------------------|
|                                                  |              | <b>2011</b>         | <b>2010</b>      |
|                                                  | <b>Notes</b> | <b>\$</b>           | <b>\$</b>        |
| <b>Current</b>                                   |              |                     |                  |
| Trade receivables, third parties                 | (i)          | 3,852,356           | 3,680,579        |
| Other receivables                                | (ii)         | 264,223             | 522,595          |
| Current income tax receivable                    |              | 22,568              | 92,313           |
| <b>Total Current trade and other receivables</b> |              | <b>4,139,147</b>    | <b>4,295,487</b> |
| <b>Non-current</b>                               |              |                     |                  |
| Other receivables                                |              | 80,087              | 161,500          |
| <b>Total Non-current other receivables</b>       |              | <b>80,087</b>       | <b>161,500</b>   |

#### Terms and conditions

Terms and conditions relating to the above financial instruments

- (i) Trade receivables are non-interest bearing and generally on 30 and 60 day terms.
- (ii) Other debtors are non-interest bearing and have repayment terms between 30 and 90 days.
- (iii) Related party details are set out in the Note 19 Related party disclosures, controlled entities.

The following table details the Group's trade and other current receivables exposed to credit risk (prior to collateral and other credit enhancements) with ageing analysis and impairment provided for thereon. Amounts are considered as "past due" when the debt has not been settled, with the terms and conditions agreed between the Group and the customer or counterparty to the transaction. Receivables that are past due are assessed for impairment by ascertaining solvency of the debtors and are provided for where there are specific circumstances indicating that the debt may not be fully repaid to the Group.

The balances of receivables that remain with initial trade terms (as detailed in the table) are considered to be of high credit quality.

|                                           | Gross Amount | Past Due and Impaired | Past Due but Not Impaired |         |         |         | Within Initial Trade Terms |
|-------------------------------------------|--------------|-----------------------|---------------------------|---------|---------|---------|----------------------------|
|                                           |              |                       | (Days Overdue)            |         |         |         |                            |
|                                           |              |                       | < 30                      | 31 - 60 | 61 - 90 | > 90    |                            |
|                                           | \$           | \$                    | \$                        | \$      | \$      | \$      | \$                         |
| 2011                                      |              |                       |                           |         |         |         |                            |
| Trade receivables, third parties          | 3,852,356    | -                     | 70,883                    | 90,704  | 11,575  | 13,333  | 3,665,861                  |
| Other receivables - current               | 264,223      | -                     | -                         | -       | -       | 40,043  | 224,180                    |
| Total trade and other current receivables | 4,116,579    | -                     | 70,883                    | 90,704  | 11,575  | 53,376  | 3,890,041                  |
| 2010                                      |              |                       |                           |         |         |         |                            |
| Trade receivables, third parties          | 3,680,579    | -                     | 39,854                    | 21,407  | 6,418   | 56,145  | 3,556,755                  |
| Other receivables - current               | 522,595      | -                     | -                         | -       | -       | 323,088 | 199,507                    |
| Total trade and other current receivables | 4,203,174    | -                     | 39,854                    | 21,407  | 6,418   | 379,233 | 3,756,262                  |

### 9. INVENTORIES

|                                                          | Consolidated     |                  |
|----------------------------------------------------------|------------------|------------------|
|                                                          | 2011             | 2010             |
|                                                          | \$               | \$               |
| <b>Current</b>                                           |                  |                  |
| Raw materials at cost                                    | 705,537          | 625,955          |
| Finished goods at low er of cost or net realisable value | 1,781,544        | 1,920,912        |
| <b>Total current inventory</b>                           | <b>2,487,081</b> | <b>2,546,867</b> |
| <b>Non-current</b>                                       |                  |                  |
| Finished goods at low er of cost or net realisable value | -                | 702,000          |
| <b>Total non-current inventory</b>                       | <b>-</b>         | <b>702,000</b>   |
| <b>Total inventory</b>                                   | <b>2,487,081</b> | <b>3,248,867</b> |

### 10. PROPERTY, PLANT AND EQUIPMENT

| Year ended                 |                                    |                           |                        |                                  |                             |                   |
|----------------------------|------------------------------------|---------------------------|------------------------|----------------------------------|-----------------------------|-------------------|
| 31 December 2011           | Leasehold<br>Land and<br>buildings | Leasehold<br>improvements | Plant and<br>equipment | Leased Plant<br>and<br>Equipment | Capital Work<br>in Progress | Total             |
| Consolidated               | \$                                 | \$                        | \$                     | \$                               | \$                          | \$                |
| <b>1 January 2011</b>      |                                    |                           |                        |                                  |                             |                   |
| at written down value      | 1,980,468                          | 2,833,764                 | 5,205,297              | 26,962                           | 13,037                      | 10,059,528        |
| Additions / Transfers      | -                                  | -                         | 290,368                | -                                | 20,250                      | 310,618           |
| Disposals / Transfers      | -                                  | -                         | (21,541)               | -                                | (13,037)                    | (34,578)          |
| Depreciation for the year  | (49,457)                           | (76,703)                  | (485,198)              | (6,722)                          | -                           | (618,080)         |
| <b>31 December 2011</b>    |                                    |                           |                        |                                  |                             |                   |
| at written down value      | <b>1,931,011</b>                   | <b>2,757,061</b>          | <b>4,988,926</b>       | <b>20,240</b>                    | <b>20,250</b>               | <b>9,717,488</b>  |
| <b>1 January 2011</b>      |                                    |                           |                        |                                  |                             |                   |
| Cost value                 | 1,983,729                          | 3,033,163                 | 7,053,894              | 141,011                          | 13,037                      | 12,224,834        |
| Accumulated depreciation   | (3,261)                            | (199,399)                 | (1,848,597)            | (114,049)                        | -                           | (2,165,306)       |
| <b>Net carrying amount</b> | <b>1,980,468</b>                   | <b>2,833,764</b>          | <b>5,205,297</b>       | <b>26,962</b>                    | <b>13,037</b>               | <b>10,059,528</b> |
| <b>31 December 2011</b>    |                                    |                           |                        |                                  |                             |                   |
| Cost value                 | 1,983,729                          | 3,033,163                 | 7,336,642              | 141,011                          | 20,250                      | 12,514,795        |
| Accumulated depreciation   | (52,718)                           | (276,102)                 | (2,347,716)            | (120,771)                        | -                           | (2,797,307)       |
| <b>Net carrying amount</b> | <b>1,931,011</b>                   | <b>2,757,061</b>          | <b>4,988,926</b>       | <b>20,240</b>                    | <b>20,250</b>               | <b>9,717,488</b>  |

Property, plant and equipment is secured against the Fixed and Floating charge held by the National Australia Bank as set out in Note 14 (b).

### 10. PROPERTY, PLANT AND EQUIPMENT (continued)

Year ended

31 December 2010

|                            | Land and<br>buildings | Leasehold<br>improvements | Plant and<br>equipment | Leased Plant<br>and<br>Equipment | Capital Work<br>in Progress | Total             |
|----------------------------|-----------------------|---------------------------|------------------------|----------------------------------|-----------------------------|-------------------|
| Consolidated               | \$                    | \$                        | \$                     | \$                               | \$                          | \$                |
| <b>1 January 2010</b>      |                       |                           |                        |                                  |                             |                   |
| at written down value      | 161,500               | 19,631                    | 726,433                | -                                | 4,145,387                   | 5,052,951         |
| Additions / Transfers      | 1,983,729             | 2,825,047                 | 5,091,490              | 26,962                           | -                           | 9,927,228         |
| Disposals / Transfers      | (161,500)             | -                         | (324,667)              | -                                | (4,132,350)                 | (4,618,517)       |
| Depreciation for the year  | (3,261)               | (10,914)                  | (287,960)              | -                                | -                           | (302,134)         |
| <b>31 December 2010</b>    |                       |                           |                        |                                  |                             |                   |
| at written down value      | <b>1,980,468</b>      | <b>2,833,764</b>          | <b>5,205,297</b>       | <b>26,962</b>                    | <b>13,037</b>               | <b>10,059,528</b> |
| <b>1 January 2010</b>      |                       |                           |                        |                                  |                             |                   |
| Cost value                 | 161,500               | 208,116                   | 2,527,570              | 114,049                          | 4,145,387                   | 7,156,622         |
| Accumulated depreciation   | -                     | (188,485)                 | (1,801,137)            | (114,049)                        | -                           | (2,103,671)       |
| <b>Net carrying amount</b> | <b>161,500</b>        | <b>19,631</b>             | <b>726,433</b>         | <b>-</b>                         | <b>4,145,387</b>            | <b>5,052,951</b>  |
| <b>31 December 2010</b>    |                       |                           |                        |                                  |                             |                   |
| Cost value                 | 1,983,729             | 3,033,163                 | 7,053,894              | 141,011                          | 13,037                      | 12,224,834        |
| Accumulated depreciation   | (3,261)               | (199,400)                 | (1,848,598)            | (114,049)                        | -                           | (2,165,307)       |
| <b>Net carrying amount</b> | <b>1,980,468</b>      | <b>2,833,764</b>          | <b>5,205,297</b>       | <b>26,962</b>                    | <b>13,037</b>               | <b>10,059,528</b> |

### 11. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

|                      |  |  |  |  | <b>Consolidated</b> |             |
|----------------------|--|--|--|--|---------------------|-------------|
|                      |  |  |  |  | <b>2011</b>         | <b>2010</b> |
|                      |  |  |  |  | <b>\$</b>           | <b>\$</b>   |
| Associated companies |  |  |  |  | -                   | 188,231     |

| <b>Name</b>                       | <b>Principal Activities</b> | <b>Country of Incorporation</b> | <b>Shares</b> | <b>Ownership Interest</b> |             |
|-----------------------------------|-----------------------------|---------------------------------|---------------|---------------------------|-------------|
|                                   |                             |                                 |               | <b>2011</b>               | <b>2010</b> |
| Macquarie Medical Imaging Pty Ltd | Imaging centre              | Australia                       | Preference    | 20%                       | 20%         |

|                                   |              | <b>Consolidated</b> |             |
|-----------------------------------|--------------|---------------------|-------------|
|                                   |              | <b>2011</b>         | <b>2010</b> |
|                                   |              | <b>\$</b>           | <b>\$</b>   |
| Macquarie Medical Imaging Pty Ltd | At 1 January | 188,231             | -           |
| Investment in associate           |              | 400,000             | 500,000     |
| Sales to associate                |              | (4,958)             | (397)       |
| Share of losses after income tax  |              | (583,273)           | (311,372)   |
| At 31 December                    |              | -                   | 188,231     |

|                                                                      |  | <b>Consolidated</b> |             |
|----------------------------------------------------------------------|--|---------------------|-------------|
|                                                                      |  | <b>2011</b>         | <b>2010</b> |
|                                                                      |  | <b>\$</b>           | <b>\$</b>   |
| <b>Extract from the associate's statement of financial position:</b> |  |                     |             |
| Current Assets                                                       |  | 1,827,090           | 2,100,522   |
| Non-current Assets                                                   |  | 3,738,057           | 4,108,207   |
| Current Liabilities                                                  |  | (3,380,120)         | (1,413,137) |
| Non-current Liabilities                                              |  | (3,603,380)         | (3,652,567) |
| Net assets                                                           |  | (1,418,353)         | 1,143,025   |
| Share of associate's net assets                                      |  | (283,671)           | 228,605     |

|                                                                        |  | <b>Consolidated</b> |             |
|------------------------------------------------------------------------|--|---------------------|-------------|
|                                                                        |  | <b>2011</b>         | <b>2010</b> |
|                                                                        |  | <b>\$</b>           | <b>\$</b>   |
| <b>Extract from the associate's statement of comprehensive income:</b> |  |                     |             |
| Revenue                                                                |  | 4,164,353           | 1,313,215   |
| Net Loss                                                               |  | (3,521,642)         | (1,556,857) |

### 11. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD (continued)

Cyclopharm's wholly owned subsidiary Cyclopet Pty Ltd has invested \$400,000 (2010: \$500,000) in Macquarie Medical Imaging Pty Ltd, an imaging joint venture at Macquarie University Hospital. Cyclopet Pty Ltd has a 20% (2010: 20%) interest in Macquarie Medical Imaging Pty Ltd.

The share of the associate's loss as at 31 December 2011 was \$583,273 (31 December 2010: \$311,372). The unrecognised share of losses of Macquarie Medical Imaging Pty Ltd both for the period and cumulatively are \$121,055.

The fair value of the Group's investment in Macquarie Medical Imaging Pty Ltd is \$nil (2010: \$188,231).

|                                                                                                                                                                 | Consolidated |           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------|
|                                                                                                                                                                 | 2011         | 2010      |
|                                                                                                                                                                 | \$           | \$        |
| <b>Contingent liabilities relating to the associate:</b>                                                                                                        |              |           |
| Share of contingent liabilities incurred jointly with other investors to guarantee the associate's financing facilities for which the Group is severally liable | 3,200,000    | 3,200,000 |

The guarantee by Cyclopharm Limited and Cyclopet Pty Limited jointly given with other investors is security for the whole Macquarie Medical Imaging Pty Ltd financing facility provided by the Commonwealth Bank of Australia. Cyclopharm Group's liability is limited to the amount that Cyclopharm Limited and Cyclopet Pty Ltd are obliged to fund under a Subscription Agreement which at the date of this report is 20% of the liability. This has also been disclosed as a Contingent Liability in Note 18 (e).

### 12. INTANGIBLE ASSETS

|                         | Intellectual<br>Property | Technegas<br>Development | FDA<br>Development | Total            |
|-------------------------|--------------------------|--------------------------|--------------------|------------------|
| Consolidated            | \$                       | \$                       | \$                 | \$               |
| <b>Balance at</b>       |                          |                          |                    |                  |
| <b>1 January 2011</b>   | 129,702                  | 131,196                  | 2,360,254          | 2,621,152        |
| Additions               | 18,407                   | -                        | 220,283            | 238,690          |
| Amortisation            | (20,808)                 | (30,720)                 | -                  | (51,528)         |
| <b>Balance at</b>       |                          |                          |                    |                  |
| <b>31 December 2011</b> | <b>127,301</b>           | <b>100,476</b>           | <b>2,580,537</b>   | <b>2,808,314</b> |
| <b>31 December 2011</b> |                          |                          |                    |                  |
| Non-Current             | 127,301                  | 100,476                  | 2,580,537          | 2,808,314        |
| <b>Total</b>            | <b>127,301</b>           | <b>100,476</b>           | <b>2,580,537</b>   | <b>2,808,314</b> |
| <b>31 December 2010</b> |                          |                          |                    |                  |
| Non-Current             | 129,702                  | 131,196                  | 2,360,254          | 2,621,152        |
| <b>Total</b>            | <b>129,702</b>           | <b>131,196</b>           | <b>2,360,254</b>   | <b>2,621,152</b> |

### 12. INTANGIBLE ASSETS (continued)

Intellectual Property and Technegas Development assets have finite useful lives. The current amortisation charges are included under depreciation and amortisation expense in the statement of comprehensive income. The recoverable amount of FDA and Technegas development costs have been assessed using a discounted cash flow methodology forecasting five years of pre-tax cash flows.

The following describes each key assumption on which management has based its value in use calculations:

- (a) Five year pre- tax cash flow projections, based upon management approved budgets and growth rates covering a one year period, with the subsequent periods based upon management expectations of growth excluding the impact of possible future acquisitions, business improvement capital expenditure and restructuring. Initial sales (following the approval by the FDA allowing the sale of Technegas generators and PAS units in the US) is forecasted to commence in 2015 with significant growth forecasted for 2016 and subsequent years.
- (b) The discount factor used was 7.2% in 2011 (2010: 7.2%).
- (c) The Directors have concluded that the recoverable amount of the FDA development costs and other intangibles exceed their carrying value.
- (d) In December 2011, the Company received approval from the US FDA to commence Phase III Clinical trials for Technegas indicating that the design of the Phase III development program and clinical trial for Technegas is suitable to support regulatory approval for the United States.
- (e) The FDA clinical trials are expected to cost US\$3.7 million over the next 3 years.

### 13. TRADE AND OTHER PAYABLES

|                                       |       | Consolidated     |                  |
|---------------------------------------|-------|------------------|------------------|
|                                       |       | 2011             | 2010             |
|                                       | Notes | \$               | \$               |
| Trade payables, third parties         | (i)   | 639,053          | 688,933          |
| Other payables and accruals           | (ii)  | 471,353          | 393,559          |
| <b>Total trade and other payables</b> |       | <b>1,110,406</b> | <b>1,082,492</b> |

#### Terms and conditions

Terms and conditions relating to the above financial instruments:

- (i) Trade payables are non-interest bearing and are normally settled on 30-60 day terms.
- (ii) Other payables and accruals are non-interest bearing and have an average term of 4 months.
- (iii) The non-interest bearing loan, related party loan is payable when called upon. Related party details are set out in the Note 19 Related party disclosures, controlled entities.

## 14. INTEREST BEARING LOANS AND BORROWINGS

|                                                            | Consolidated     |                  |
|------------------------------------------------------------|------------------|------------------|
|                                                            | 2011<br>\$       | 2010<br>\$       |
| <b>Current</b>                                             |                  |                  |
| Lease liability - secured                                  | 3,156            | 2,400            |
| Bank loan - secured (b)                                    | 4,800,000        | 6,075,900        |
| <b>Interest bearing loans and borrowings (current)</b>     | <b>4,803,156</b> | <b>6,078,300</b> |
| <b>Non-current</b>                                         |                  |                  |
| Lease liability - secured                                  | 21,297           | 24,453           |
| <b>Interest bearing loans and borrowings (non-current)</b> | <b>21,297</b>    | <b>24,453</b>    |

### a) Financing facilities available:

At reporting date, the following financing facilities had been negotiated and were available:

|                                             | Notes | Consolidated     |                  |
|---------------------------------------------|-------|------------------|------------------|
|                                             |       | 2011<br>\$       | 2010<br>\$       |
| <b>Total facilities available:</b>          |       |                  |                  |
| - secured bank loans, third party           |       | 4,800,000        | 6,075,900        |
|                                             |       | <b>4,800,000</b> | <b>6,075,900</b> |
| <b>Facilities used at reporting date:</b>   |       |                  |                  |
| - secured bank loans, third party           | 14    | 4,800,000        | 6,075,900        |
|                                             |       | <b>4,800,000</b> | <b>6,075,900</b> |
| Total facilities                            |       | 4,800,000        | 6,075,900        |
| Facilities used at reporting date:          |       | (4,800,000)      | (6,075,900)      |
| <b>Facilities unused at reporting date:</b> |       | <b>-</b>         | <b>-</b>         |

### 14. INTEREST BEARING LOANS AND BORROWINGS (continued)

#### (b) Secured Bank Loans

Cyclopharm has a flexible rate loan provided by the National Australia Bank. The facility expires in December 2015. The facility is secured by a first registered mortgage debenture over Cyclopharm Limited and a guarantee and indemnity from Cyclomedica Australia Pty Ltd, CycloPET Pty Ltd, Allrad No. 28 Pty Ltd and Allrad No. 29 Pty Ltd. The National Australia Bank has a registered Fixed and Floating Charge and First Registered Debenture charges over these companies.

The Group has breached one of its banking covenants during the year ended 31 December 2011, being an Event of Default triggered by variances greater than 15% of Actual Earnings Before Interest and Taxes (EBIT) as compared to Budgeted EBIT. The bank has agreed not to take action at this point in time.

### 15. PROVISIONS

|                                 | Consolidated          |
|---------------------------------|-----------------------|
|                                 | Employee Entitlements |
| Consolidated                    | \$                    |
| <b>Balance at</b>               |                       |
| <b>1 January 2011</b>           | <b>526,993</b>        |
| Arising during the year         | 269,508               |
| Utilised                        | (86,375)              |
| <b>Balance at</b>               |                       |
| <b>31 December 2011</b>         | <b>710,126</b>        |
| <b>31 December 2011</b>         |                       |
| <b>Current</b>                  | <b>645,716</b>        |
| <b>Non-Current</b>              | <b>64,410</b>         |
| <b>Total</b>                    | <b>710,126</b>        |
| <b>Number of employees</b>      |                       |
| Number of employees at year end | 33                    |
| <b>31 December 2010</b>         |                       |
| <b>Current</b>                  | <b>499,283</b>        |
| <b>Non-Current</b>              | <b>27,710</b>         |
| <b>Total</b>                    | <b>526,993</b>        |
| <b>Number of employees</b>      |                       |
| Number of employees at year end | 38                    |

A provision has been recognised for employee entitlements relating to long service leave. The measurement and recognition criteria relating to employee benefits have been included in Note 2.

# Notes

## Continued

### 16. CONTRIBUTED EQUITY

|                                                |       | Consolidated       |                    |                   |                   |
|------------------------------------------------|-------|--------------------|--------------------|-------------------|-------------------|
|                                                | Notes | 2011<br>Number     | 2010<br>Number     | 2011<br>\$        | 2010<br>\$        |
| <b>Issued and paid up capital</b>              |       |                    |                    |                   |                   |
| Ordinary shares                                | (a)   | 223,579,418        | 171,012,616        | 18,398,350        | 16,422,066        |
| Other contributed equity                       | (b)   | -                  | -                  | (5,333,158)       | (5,333,158)       |
| <b>Total issued and paid up capital</b>        |       | <b>223,579,418</b> | <b>171,012,616</b> | <b>13,065,192</b> | <b>11,088,908</b> |
| <b>Ordinary shares</b>                         |       |                    |                    |                   |                   |
| <b>(a) Issued and paid up capital</b>          |       |                    |                    |                   |                   |
| Balance at the beinning of the period          |       | 171,012,616        | 171,012,616        | 16,422,066        | 16,422,066        |
| Issue of renounceable rights shares            | (i)   | 52,566,802         | -                  | 1,976,284         | -                 |
| Balance at end of period                       |       | <b>223,579,418</b> | <b>171,012,616</b> | <b>18,398,350</b> | <b>16,422,066</b> |
| <b>(b) Other contributed equity</b>            |       |                    |                    |                   |                   |
| Balance at the beginning and end of the period |       | -                  | -                  | (5,333,158)       | (5,333,158)       |

Ordinary shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares entitle their holder to one vote, either in person or by proxy, at a meeting of the Company.

- (i) On 8 December 2011, the Company completed a capital raising exercise comprising a pro-rata renounceable entitlement offer to eligible shareholders of 1 share for every 3.2 shares held by eligible shareholders at an issue price of \$0.04 per rights share resulting in the issue of 52,566,802 shares, raising \$2,102,672 before share issue costs of \$126,388.

### 16. CONTRIBUTED EQUITY (continued)

The Group's debt and capital includes ordinary share capital and financial liabilities supported by financial assets. When managing capital, management's objective is to ensure the entity continues as a going concern as well as to maintain optimal returns for shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.

Management constantly assess the capital structure to take advantage of favourable costs of capital and/or high returns on assets. As the market is continually changing, management may issue dividends to shareholders, issue new shares, increase its short or long term borrowings or sell assets to reduce borrowings.

The Directors did not declare a dividend during the financial year ended 31 December 2011.

Management monitors capital through the gearing ratio (net debt/total capital). Management aim to ensure that the Group's gearing ratio does not exceed 45%. The Group has breached one of its banking covenants during the year ended 31 December 2011, being an Event of Default triggered by variances greater than 15% of Actual Earnings Before Interest and Taxes (EBIT) as compared to Budgeted EBIT. The bank has agreed not to take action at this point in time.

|                                             |   | Consolidated     |                  |
|---------------------------------------------|---|------------------|------------------|
|                                             |   | 2011             | 2010             |
| Notes                                       |   | \$               | \$               |
| Total interest bearing loans and borrowings |   | 4,824,453        | 6,102,753        |
| Less cash and cash equivalents              | 7 | (2,043,814)      | (1,541,644)      |
| Net debt                                    |   | <b>2,780,639</b> | <b>4,561,109</b> |
| Total equity                                |   | 14,604,799       | 13,766,154       |
| Gearing ratio                               |   | 19.0%            | 33.1%            |

### 17. FINANCIAL RISK MANAGEMENT OBJECTIVES

The Group's principal financial instruments comprise receivables, payables, bank loans, cash and short-term deposits. The Group manages its exposure to key financial risks, including interest rate and currency risk in accordance with the Group's financial risk management policy. The objective of the policy is to support the delivery of the Group's financial targets while protecting future financial security.

The Group uses different methods to measure and manage different types of risks to which it is exposed. These include monitoring levels of exposure to interest rate, foreign exchange risk and assessments of market forecasts for interest rate, foreign exchange and commodity prices. Ageing analysis and monitoring of specified credit allowances are undertaken to manage credit risk, liquidity risk is monitored through the development of future rolling cash flow forecasts.

The Board review and agrees policies for managing each of these risks as summarised below.

Primary responsibility for identification and control of financial risks rests with the Audit and Risk Management Committee under the authority from the Board. The Board reviews and agrees policies for managing each of the risks identified below, including for interest rate risk, credit allowances and cash flow forecast projections. It is, and has been throughout the year under review, the Group's policy that no trading in financial instruments shall be undertaken.

Details of the significant accounting policies and methods adopted, including the criteria for recognition, the basis of measurement and the basis on which income and expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are disclosed in Note 2.

### (a) Interest rate risk

The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's long term debt obligations with a floating interest rate. The Group's policy is to manage its interest cost using a mix of fixed and variable rate debt. The Group constantly analyses its interest rate exposure. Within this analysis consideration is given to potential renewals of existing positions, alternative financing, positions and the mix of fixed and variable interest rates.

The following sensitivity analysis is based on the interest rate risk exposures in existence at the Statement of Financial Position date.

At 31 December 2011, if interest rates had moved, as illustrated in the table below, with all other variables held constant, pre-tax profit would have been affected as follows:

|                                              | Consolidated |          |
|----------------------------------------------|--------------|----------|
|                                              | 2011         | 2010     |
|                                              | \$           | \$       |
| Judgements of reasonably possible movements: |              |          |
| <b>Profit / (Loss) before income tax</b>     |              |          |
| +1.0% (100 basis points)                     | (54,379)     | (44,046) |
| -0.5% (50 basis points)                      | 27,190       | 22,023   |

The movements in profit are due to possible higher or lower interest costs from variable rate debt and cash balances.

# Notes

## Continued

### 17. FINANCIAL RISK MANAGEMENT OBJECTIVES (continued)

At balance date, the Group had the following mix of financial assets and liabilities exposed to variable interest rate risk:

#### (a) Cash flow interest rate risk (continued)

| Consolidated                       |      |                                  |                      |                        | Floating interest maturing in |                 |                    |
|------------------------------------|------|----------------------------------|----------------------|------------------------|-------------------------------|-----------------|--------------------|
| Year ended                         | Note | Weighted average interest rate % | Non interest bearing | Floating interest rate | 1 year or less                | 1 to 5 years    | Total              |
| <b>31 December 2011</b>            |      |                                  |                      |                        |                               |                 |                    |
| <b>FINANCIAL ASSETS</b>            |      |                                  |                      |                        |                               |                 |                    |
| Cash and cash equivalents          | 7    | 4.25%                            | -                    | 2,043,814              | -                             | -               | 2,043,814          |
| Trade and other receivables        | 8    | n/a                              | 4,139,147            | -                      | -                             | -               | 4,139,147          |
| <b>Total financial assets</b>      |      |                                  | <b>4,139,147</b>     | <b>2,043,814</b>       | <b>-</b>                      | <b>-</b>        | <b>6,182,961</b>   |
| <b>FINANCIAL LIABILITIES</b>       |      |                                  |                      |                        |                               |                 |                    |
| Trade payables, third parties      | 13   | n/a                              | 1,110,406            | -                      | -                             | -               | 1,110,406          |
| Leases, third party                | 14   | 16.76%                           | -                    | -                      | 3,156                         | 21,297          | 24,453             |
| Secured bank loans, third party    | 14   | 6.34%                            | -                    | -                      | 4,800,000                     | -               | 4,800,000          |
| Employee entitlements              | 15   | n/a                              | 710,126              | -                      | -                             | -               | 710,126            |
| <b>Total financial liabilities</b> |      |                                  | <b>1,820,532</b>     | <b>-</b>               | <b>4,803,156</b>              | <b>21,297</b>   | <b>6,644,985</b>   |
| <b>Net exposure</b>                |      |                                  | <b>2,318,615</b>     | <b>2,043,814</b>       | <b>(4,803,156)</b>            | <b>(21,297)</b> | <b>(462,024)</b>   |
| <b>31 December 2010</b>            |      |                                  |                      |                        |                               |                 |                    |
| <b>FINANCIAL ASSETS</b>            |      |                                  |                      |                        |                               |                 |                    |
| Cash and cash equivalents          | 7    | 4.70%                            | -                    | 1,541,644              | -                             | -               | 1,541,644          |
| Trade and other receivables        | 8    | n/a                              | 4,295,487            | -                      | -                             | -               | 4,295,487          |
| <b>Total financial assets</b>      |      |                                  | <b>4,295,487</b>     | <b>1,541,644</b>       | <b>-</b>                      | <b>-</b>        | <b>5,837,131</b>   |
| <b>FINANCIAL LIABILITIES</b>       |      |                                  |                      |                        |                               |                 |                    |
| Trade payables, third parties      | 13   | n/a                              | 1,082,492            | -                      | -                             | -               | 1,082,492          |
| Leases, third party                | 14   | 16.76%                           | -                    | -                      | 2,400                         | 24,453          | 26,853             |
| Secured bank loans, third party    | 14   | 7.01%                            | -                    | -                      | 6,075,900                     | -               | 6,075,900          |
| Employee entitlements              | 15   | n/a                              | 526,993              | -                      | -                             | -               | 526,993            |
| <b>Total financial liabilities</b> |      |                                  | <b>1,609,485</b>     | <b>-</b>               | <b>6,078,300</b>              | <b>24,453</b>   | <b>7,712,238</b>   |
| <b>Net exposure</b>                |      |                                  | <b>2,686,002</b>     | <b>1,541,644</b>       | <b>(6,078,300)</b>            | <b>(24,453)</b> | <b>(1,875,107)</b> |

### 17. FINANCIAL RISK MANAGEMENT OBJECTIVES (continued)

#### (b) Credit risk

Credit risk arises from the financial assets of the Group, which comprise cash and cash equivalents and trade and other receivables. The Group's exposure to credit risk arises from potential default of the counter party, with a maximum exposure equal to the carrying amount of these instruments. Exposure at balance date is addressed in each applicable note.

The Group does not hold any credit derivatives to offset its credit exposure.

The Group trades only with recognised, creditworthy third parties and as such collateral is not requested nor is it the Group's policy to scrutinise its trade and other receivables. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures such as reviewing their industry reputation, financial position and credit rating. In addition, receivable balances are monitored on an ongoing basis with the result that the Group's exposure to bad debts is constantly managed.

There are no significant unprovided concentrations of credit risk within the Group.

#### (c) Liquidity risk

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts and bank loans.

The Group's policy is to monitor the maturity of borrowings at all times. At 31 December 2011, 100% of the Group's debt will mature in less than one year (2010: 100%).

Refer to the table above with the heading 17 (a) Cash flow interest rate risk which reflects all contractually fixed pay-offs for settlement of financial liabilities and collection of financial assets. Trade payables and other financial liabilities generally originate from the financing of assets used in our ongoing operations such as investments in working capital eg inventories and trade receivables and investment in property, plant and equipment. These assets are considered in the Group's overall liquidity risk. To monitor existing financial assets and liabilities as well as to enable an effective controlling of future risks, the board and management monitors the Group's expected settlement of financial assets and liabilities on an ongoing basis.

The Group monitors rolling forecast of liquidity reserves on the basis of expected cash flow. At balance date the Group has no unused credit facilities (2010: \$nil).

| Consolidated<br>Year ended      | Note | Less than 6<br>months | 6 months to 1<br>year | 1 year to 5<br>years | Greater than<br>5 years | Total     |
|---------------------------------|------|-----------------------|-----------------------|----------------------|-------------------------|-----------|
| <b>31 December 2011</b>         |      |                       |                       |                      |                         |           |
| Trade payables, third parties   | 13   | 1,110,406             | -                     | -                    | -                       | 1,110,406 |
| Leases, third party             | 14   | -                     | 3,156                 | 21,297               | -                       | 24,453    |
| Secured bank loans, third party | 14   | 600,000               | 4,200,000             | -                    | -                       | 4,800,000 |
|                                 |      | 1,710,406             | 4,203,156             | 21,297               | -                       | 5,934,859 |
| <b>31 December 2010</b>         |      |                       |                       |                      |                         |           |
| Trade payables, third parties   | 13   | 1,082,492             | -                     | -                    | -                       | 1,082,492 |
| Leases, third party             | 14   | -                     | 2,400                 | 24,453               | -                       | 26,853    |
| Secured bank loans, third party | 14   | -                     | 6,075,900             | -                    | -                       | 6,075,900 |
|                                 |      | 1,082,492             | 6,078,300             | 24,453               | -                       | 7,185,245 |

#### (d) Commodity price risk

The Group's exposure to commodity price risk is minimal.

### 17. FINANCIAL RISK MANAGEMENT OBJECTIVES (continued)

#### (e) Foreign currency risk

As a result of significant investment operations in Europe, the Group's Statement of Financial Position can be affected significantly by movements in the EURO / A\$ exchange rates. The Group does not hedge this exposure.

The Group also has transactional currency exposures. Such exposure arises from sales or purchases by an operating unit in currencies other than the unit's functional currency. Approximately 72% (2010: 80%) of the Group's sales are denominated in currencies other than the functional currency of the operating unit making the sale, whilst approximately 71% (2010: 69%) of costs are denominated in the unit's functional currency.

At 31 December 2011, the Group had the following financial instrument exposure to foreign currency fluctuations:

|                              | <b>Consolidated</b> |                    |
|------------------------------|---------------------|--------------------|
|                              | <b>2011</b>         | <b>2010</b>        |
|                              | <b>\$</b>           | <b>\$</b>          |
| <b>United States dollars</b> |                     |                    |
| Amounts payable              | 8,872               | 79,456             |
| Amounts receivable           | 17,051              | 115,787            |
| <b>Euros</b>                 |                     |                    |
| Amounts payable              | 188,607             | 317,164            |
| Amounts receivable           | 2,663,781           | 2,695,532          |
| <b>Canadian dollars</b>      |                     |                    |
| Amounts payable              | 1,876               | 4,729              |
| Amounts receivable           | 362,549             | 356,688            |
| <b>Net exposure</b>          | <b>(2,844,026)</b>  | <b>(2,766,658)</b> |

Management believe the balance date risk exposures are representative of the risk exposure inherent in the financial instruments.

#### Fair values

All of the Group's financial instruments recognised in the Statement of Financial Position have been assessed at their fair values.

### 17. FINANCIAL RISK MANAGEMENT OBJECTIVES (continued)

#### (e) Foreign currency risk (continued)

##### Foreign currency sensitivity

Currency risk is measured using sensitivity analysis. A portion of Cyclopharm's receivables and payables are exposed to movements in the values of those currencies relative to the Australian dollar. Cyclopharm management have determined that it is not cost effective to hedge against foreign currency fluctuations.

Cyclopharm is exposed to European Euro (Euro), Canadian Dollar (CAD) and US Dollar (USD) movements. The following table details Cyclopharm's sensitivity to a 10% change in the Australian dollar against respective currencies with all other variables held constant as at reporting date for unhedged foreign exposure risk. A positive number indicates an increase in net profit/equity.

A sensitivity has been selected as this is considered reasonable given the current level of exchange rates and the volatility observed on a historic basis and market expectation for future movement.

|                              | Consolidated              |                           |
|------------------------------|---------------------------|---------------------------|
|                              | Increase in AUD<br>of 10% | Decrease in<br>AUD of 10% |
|                              | \$                        | \$                        |
| <b>Euro</b>                  |                           |                           |
| <b>31 December 2011</b>      |                           |                           |
| Net loss                     | (1,181,236)               | (708,703)                 |
| Equity (decrease)            | (1,181,236)               | (708,703)                 |
| <b>31 December 2010</b>      |                           |                           |
| Net (loss) / profit          | (162,471)                 | 198,574                   |
| Equity (decrease) / increase | (162,471)                 | 198,574                   |

### 18. COMMITMENTS & CONTINGENCIES

#### (a) Operating lease commitments

Future minimum rentals payable under non-cancellable operating leases are as follows:

|                                                                   | Consolidated     |                  |
|-------------------------------------------------------------------|------------------|------------------|
|                                                                   | 2011             | 2010             |
|                                                                   | \$               | \$               |
| <b>Operating Lease Commitments</b>                                |                  |                  |
| <b>Minimum lease payments</b>                                     |                  |                  |
| Due not later than one year                                       | 491,537          | 432,441          |
| Due later than 1 year & not later than 5 years                    | 1,155,100        | 1,123,854        |
| More than 5 years                                                 | 1,066,176        | 1,332,720        |
| <b>Total operating lease commitments</b>                          | <b>2,712,813</b> | <b>2,889,015</b> |
| Operating lease expenses recognised as an expense during the year | 487,506          | 165,897          |

- The Group has entered into commercial leases on office space within certain buildings. These leases have an average life of between 3 to 5 years with renewal options included in the contracts. There are no restrictions placed upon the lessee by entering into these leases.
- Cyclopet Pty Ltd has entered into a commercial lease for the PET Facility at Macquarie University Hospital. The lease has a term of 10 years and commenced upon commissioning of the Hospital in June 2010.
- The Group also has entered into commercial leases on motor vehicles that have an average life of approximately 3 to 5 years.

#### (b) Finance lease commitments

|                                                | Notes | Consolidated  |               |
|------------------------------------------------|-------|---------------|---------------|
|                                                |       | 2011          | 2010          |
|                                                |       | \$            | \$            |
| <b>Finance Lease Commitments</b>               |       |               |               |
| <b>Minimum lease payments</b>                  |       |               |               |
| Due not later than one year                    | (i)   | 3,156         | 2,400         |
| Due later than 1 year & not later than 5 years | (i)   | 21,297        | 24,453        |
| <b>Total finance lease commitments</b>         |       | <b>24,453</b> | <b>26,853</b> |

- (i) The Group also has entered into a commercial lease on motor vehicles that have a life of 5 years. This lease is secured against the underlying assets.

### (c) Other commitments

|                                                         |            | Consolidated     |                  |
|---------------------------------------------------------|------------|------------------|------------------|
|                                                         |            | 2011             | 2010             |
| Notes                                                   |            | \$               | \$               |
| <b>The company has the following other commitments:</b> |            |                  |                  |
| Not later than one year                                 | (i) & (ii) | 4,800,000        | 6,075,900        |
| <b>Total</b>                                            |            | <b>4,800,000</b> | <b>6,075,900</b> |

Cyclopharm has a flexible rate loan provided by the National Australia Bank. The facility expires in December 2015. The facility is secured by a first registered mortgage debenture over Cyclopharm Limited and a guarantee and indemnity from Cyclomedica Australia Pty Ltd, CycloPET Pty Ltd, Allrad No. 28 Pty Ltd and Allrad No. 29 Pty Ltd. The National Australia Bank has a registered Fixed and Floating Charge and First Registered Debenture charges over these companies.

The Group has breached one of its banking covenants during the year ended 31 December 2011, being an Event of Default triggered by variances greater than 15% of Actual Earnings Before Interest and Taxes (EBIT) as compared to Budgeted EBIT. The bank has agreed not to take action at this point in time.

### (d) Capital commitments

There were no capital commitments as at the date of this report (2010: \$nil).

### (e) Contingent liabilities

|                                                                                                                                                                 |  | Consolidated |           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------|-----------|
|                                                                                                                                                                 |  | 2011         | 2010      |
|                                                                                                                                                                 |  | \$           | \$        |
| <b>Contingent liabilities relating to the associate:</b>                                                                                                        |  |              |           |
| Share of contingent liabilities incurred jointly with other investors to guarantee the associate's financing facilities for which the Group is severally liable |  | 3,200,000    | 3,200,000 |

The guarantee by Cyclopharm Limited and Cyclopet Pty Limited jointly given with other investors is security for the whole Macquarie Medical Imaging Pty Ltd financing facility provided by the Commonwealth Bank of Australia. Cyclopharm Group's liability is limited to the amount that Cyclopharm Limited and Cyclopet Pty Ltd are obliged to fund under a Subscription Agreement which at the date of this report is 20% of the liability.

### 19. RELATED PARTY DISCLOSURES

The consolidated financial statements include the financial statements of Cyclopharm and its subsidiaries as stated below.

The following table provides the total amount of transactions that were entered into with related parties for the relevant financial year (for information regarding outstanding balances at year-end, refer to Note 8 Trade and other receivables, Note 13 Trade and other payables and Note 14 Interest bearing loans and borrowings):

| CONSOLIDATED                 |      | Sales to<br>related<br>parties<br>\$ | Purchases<br>from related<br>parties<br>\$ | Transactions<br>with related<br>parties<br>\$ | Amounts owed<br>by related<br>parties<br>\$ | Amounts owed<br>to related parties<br>\$ |
|------------------------------|------|--------------------------------------|--------------------------------------------|-----------------------------------------------|---------------------------------------------|------------------------------------------|
| CVC Venture Managers Pty Ltd | 2011 | -                                    | -                                          | 7,274                                         | -                                           | -                                        |
|                              | 2010 | -                                    | -                                          | 16,189                                        | -                                           | 2,963                                    |
| VA Consulting Pty Ltd        | 2011 | -                                    | -                                          | 15,450                                        | -                                           | -                                        |
|                              | 2010 | -                                    | -                                          | 15,450                                        | -                                           | -                                        |
| Macquarie Medical Imaging    | 2011 | 76,526                               | -                                          | 400,000                                       | 44,051                                      | -                                        |
|                              | 2010 | 21,842                               | -                                          | 500,000                                       | 2,508                                       | -                                        |
| CVC Managers Pty Ltd         | 2011 | -                                    | -                                          | 118,057                                       | -                                           | -                                        |
|                              | 2010 | -                                    | -                                          | -                                             | -                                           | -                                        |

#### Ultimate parent entity

Cyclopharm Limited is the ultimate parent entity in the wholly owned group.

#### Terms and conditions of transactions with related parties

- During the year payments of \$7,274 (2010: \$16,189) were made to CVC Venture Managers Pty Ltd (an entity of which Mr Sharman and Mr Gould are Non-Executive Directors) in relation to the rental of office space. Mr Gould does not receive any benefits from CVC Venture Managers.
- During the year payments of \$15,450 (2010: \$15,450) were made to VA Consulting Pty Ltd (an entity controlled by Mr Sharman). All payments relate to Mr Sharman's role as a non-executive director.
- Cyclopet Pty Ltd, a wholly owned subsidiary of Cyclopharm has a 20% interest in Macquarie Medical Imaging. Cyclopet manufactures products that are sold to Macquarie Medical Imaging. Cyclopet Pty Ltd has invested \$400,000 (2010: \$500,000) in Macquarie Medical Imaging during the year.
- During the year, payments of \$118,057 (2010: \$nil) were made to CVC Managers Pty Ltd. The amount comprised of \$115,646 underwriting fees pertaining to the Company's capital raising exercise and \$2,411 interest expense in respect of a \$400,000 short term loan. The short term loan was fully repaid at the end of the financial year. Mr Gould receives director's fees, superannuation and other benefits from CVC Limited. CVC Managers Pty Limited is a wholly owned subsidiary of CVC Limited.

### Controlled Entities

| Name                              | Note | Country of Incorporation | Percentage of equity interest held |      |
|-----------------------------------|------|--------------------------|------------------------------------|------|
|                                   |      |                          | 2011                               | 2010 |
| Cyclopharm Limited                | 1,2  | Australia                |                                    |      |
| <b>Controlled entities</b>        |      |                          |                                    |      |
| CycloPET Pty Ltd                  | 2    | Australia                | 100%                               | 100% |
| Cyclomedica Australia Pty Limited | 2    | Australia                | 100%                               | 100% |
| Cyclomedica Ireland Limited       | 3    | Ireland                  | 100%                               | 100% |
| Cyclomedica Europe Limited        | 3    | Ireland                  | 100%                               | 100% |
| Cyclomedica Germany GmbH          | 5    | Germany                  | 100%                               | 100% |
| Cyclomedica Canada Limited        | 4    | Canada                   | 100%                               | 100% |
| Allrad No 28. Pty Ltd             | 2    | Australia                | 100%                               | 100% |
| Allrad No 29. Pty Ltd             | 2    | Australia                | 100%                               | 100% |

### Notes

1. Cyclopharm Limited is the ultimate parent entity in the wholly owned group.
2. Audited by Russell Bedford NSW, Australia.
3. Audited by Moore Stephens Nathans, Republic of Ireland.
4. Audited by Schwartz Levitsky & Feldman LLP, Toronto, Canada.
5. Audited by Bilanzia GmbH Wirtschaftsprüfungsgesellschaft, Germany

### 20. EVENTS AFTER THE BALANCE DATE

No matters or circumstances have arisen since the end of the financial year, not otherwise dealt with in the financial report, which significantly affected or may significantly affect the operations of the Group, financial position or the state of affairs of the Group in future financial periods.

### 21. AUDITORS' REMUNERATION

The following total remuneration was received, or is due and receivable, by auditors of the Company in respect of:

|                                                                                            | Consolidated   |                |
|--------------------------------------------------------------------------------------------|----------------|----------------|
|                                                                                            | 2011           | 2010           |
|                                                                                            | \$             | \$             |
| Amounts received or due and receivable by Russell Bedford NSW and associated entities for: |                |                |
| Audit and review of the financial statements                                               | 92,636         | 89,181         |
| Other services:                                                                            |                |                |
| - tax compliance                                                                           | 10,000         | 11,030         |
| - share registry                                                                           | 25,526         | 12,077         |
|                                                                                            | <b>128,162</b> | <b>112,288</b> |
| Amounts received or due and receivable by auditors other than Russell Bedford NSW for:     |                |                |
| Audit of the financial statements                                                          | 41,230         | 41,539         |
| Other services                                                                             | 20,122         | 21,810         |
|                                                                                            | <b>61,352</b>  | <b>63,349</b>  |

### 22. DIRECTOR AND KEY MANAGEMENT PERSONNEL DISCLOSURE

In accordance with the Corporations Amendment Regulations 2005 (No.4), the Company has transferred the remuneration disclosures required by *AASB 124: Related Party Disclosures* from the notes to the financial statements, to the Directors' Report under the heading of 'Remuneration Report'.

### 23. SHARE BASED PAYMENT PLANS

#### (a) Recognised share-based payment expenses

The expense recognised for employee services received in relation to share based payments during the year is shown in the table below:

|                                                                               | Consolidated |        |
|-------------------------------------------------------------------------------|--------------|--------|
|                                                                               | 2011         | 2010   |
|                                                                               | \$           | \$     |
| Expense arising from equity-settled share-based payment transactions (note 4) | 8,050        | 96,177 |

The share based payment reserve to 31 December 2011 was \$322,199 (2010: \$314,149).

#### (b) Type of share based payment plans

The share-based payment plan is described below. There have not been any modifications to the Long Term Incentive Plan ("Plan") following its approval by members at the Annual General Meeting held on 8 May 2007.

##### Shares

Long Term Incentive Plan ("Plan") Shares ("Shares") are granted to certain executive Directors and certain employees.

In valuing transactions settled by way of issue of shares, performance conditions and market conditions linked to the price of the shares of Cyclopharm Limited are taken into account. All shares issued have market performance conditions so as to align shareholder return and reward for the Company's selected management and staff ("Participants").

The Shares vest upon the satisfaction of certain performance conditions ("Hurdles") within the term ("Term") specified for Participants in the Plan. The Board has residual discretion to accelerate vesting (i.e. Reduce or waive the Hurdles) and exercise of Shares in the event of a takeover or merger or any other circumstance in accordance with the terms of the Plan.

Shares in relation to which Hurdles have not been satisfied (i.e. that do not vest) will lapse and will not be able to be exercised, except in the circumstances described below. Shares which have not vested will lapse where a Participant ceases employment with Cyclopharm other than on retirement, redundancy, death or total and permanent disablement or unless as otherwise determined by the Board in its absolute discretion.

Where a Participant has ceased employment with Cyclopharm as a result of resignation, retirement, redundancy, death or total and permanent disablement prior to the end of a performance period, only shares that have vested may be retained by the Participant on a pro-rata basis. If an option holder ceases employment for any reasons mentioned above prior to the first anniversary of the grant date, the Participant forfeits all entitlement to Shares.

### 23. SHARE BASED PAYMENT PLANS (continued)

#### LTIP Shares issued

At the Annual General Meeting held on 8 May 2007, Shareholders approved the Company's Plan.

#### Implied Options

*AASB 2 Share Based Payments* requires that the benefit to an employee arising from an employee share scheme such as the Cyclopharm Long Term Incentive Plan be treated as an expense in which the benefit is gained. No benefit to the employee arises from the Plan Shares as a corresponding loan applies to the issued Shares (although not required to be accounted for in the Financial Statements) instead the employee benefit is deemed to be the implied option ("Implied Option") arising from the Plan.

The International Financial Reporting Council have determined that where employee shares are issued under a non-recourse loan payment plan, the loan assets and the increment to share capital should not be recognised at grant date but rather, the transactions be treated as Implied Options. Consequently the value of the discount which has been determined using a binomial pricing model will be charged to the Statement of Comprehensive Income over the vesting period. Other increments to share capital will be recognised as the share loans are settled by the relevant employees.

#### (c) Summary of Implied Options granted

The following table illustrates movements in Implied Options during the current year:

|                                      | Consolidated<br>2011<br>Number | Consolidated<br>2010<br>Number |
|--------------------------------------|--------------------------------|--------------------------------|
| Balance at the beginning of the year | 700,000                        | 2,400,000                      |
| Granted during the year              | -                              | -                              |
| Exercised during the year            | -                              | -                              |
| Lapsed during the year               | -                              | (1,700,000)                    |
| Balance at the end of the year       | <b>700,000</b>                 | <b>700,000</b>                 |

### 23. SHARE BASED PAYMENT PLANS (continued)

#### (d) Option pricing models

The following assumptions were used to derive a value for the Implied Options granted using the Black Scholes Option model as at the grant date, taking into account the terms and conditions upon which the Shares were granted:

| <b>Exercise price per implied option</b> | <b>\$0.35</b> |
|------------------------------------------|---------------|
| Number of recipients                     | 1             |
| Number of implied options                | 700,000       |
| Grant Date                               | 3/06/2008     |
| Dividend yield                           | -             |
| Expected annual volatility               | 38%           |
| Risk-free interest rate                  | 7.25%         |
| Expected life of implied option (years)  | 4 years       |
| Fair value per implied option            | \$0.046       |
| Share price at grant date                | \$0.210       |
| Model used                               | Black Scholes |

Expected volatility percentages used for the Implied Option pricing calculations were determined using historic data over 12 months and were adjusted to reflect comparable companies in terms of industry and market capitalisation. The Implied Options arising from the Plan are not listed and as such do not have a market value.

### 24. PARENT ENTITY DISCLOSURE

|                                                                                                                                                                 | 2011              | 2010              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|
|                                                                                                                                                                 | \$                | \$                |
| <b>(i) Financial Position</b>                                                                                                                                   |                   |                   |
| <b>Assets</b>                                                                                                                                                   |                   |                   |
| Current Assets                                                                                                                                                  | 1,223,462         | 591,924           |
| Non-current Assets                                                                                                                                              | 18,560,373        | 18,094,243        |
| <b>Total Assets</b>                                                                                                                                             | <b>19,783,835</b> | <b>18,686,167</b> |
| <b>Liabilities</b>                                                                                                                                              |                   |                   |
| Current Liabilities                                                                                                                                             | 4,928,886         | 5,505,951         |
| Non-current Liabilities                                                                                                                                         | 1,063,611         | 1,264,500         |
| <b>Total Liabilities</b>                                                                                                                                        | <b>5,992,497</b>  | <b>6,770,451</b>  |
| <b>Net assets</b>                                                                                                                                               | <b>13,791,338</b> | <b>11,915,716</b> |
| <b>Equity</b>                                                                                                                                                   |                   |                   |
| Contributed equity                                                                                                                                              | 13,265,722        | 11,289,438        |
| Employee equity benefits reserve                                                                                                                                | 322,199           | 314,149           |
| Retained Profits                                                                                                                                                | 203,417           | 312,129           |
| <b>Total Equity</b>                                                                                                                                             | <b>13,791,338</b> | <b>11,915,716</b> |
| <b>(ii) Financial Performance</b>                                                                                                                               |                   |                   |
| Loss for the year                                                                                                                                               | (108,712)         | (213,679)         |
| Other comprehensive income                                                                                                                                      | -                 | -                 |
| <b>Total Loss for the year</b>                                                                                                                                  | <b>(108,712)</b>  | <b>(213,679)</b>  |
| <b>(iii) Contingent Liabilities</b>                                                                                                                             |                   |                   |
| Contingent liabilities relating to the associate:                                                                                                               |                   |                   |
| Share of contingent liabilities incurred jointly with other investors to guarantee the associate's financing facilities for which the Group is severally liable | <b>3,200,000</b>  | <b>3,200,000</b>  |

The guarantee by Cyclopharm Limited and Cyclopet Pty Limited jointly given with other investors is security for the whole Macquarie Medical Imaging Pty Ltd financing facility provided by the Commonwealth Bank of Australia. Cyclopharm Group's liability is limited to the amount that Cyclopharm Limited and Cyclopet Pty Ltd are obliged to fund under a Subscription Agreement which at the date of this report is 20% of the liability.

### 25. RESERVES

Nature and purpose of reserves:

**(a) Employee equity benefits reserve**

The employee share based payments reserve is used to record the value of share based payments provided to employees, including key management personnel, as part of their remuneration.

**(b) Foreign currency Translation Reserve**

The foreign currency translation reserve is used to record exchange differences arising from the translation of the financial statements of foreign subsidiaries.

# Director's Declaration



In the opinion of the Directors of Cyclopharm Limited:

1. (a) The financial statements and notes and of the consolidated entity are in accordance with the Corporations Act 2001, including:
    - (i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2011 and of its performance for the year ended on that date; and
    - (ii) complying with Accounting Standards and Corporations Regulations 2001: and
  - (b) The remuneration disclosures that are contained in the Remuneration Report on pages 15 to 22 of the Directors' Report comply with the Australian Accounting Standard AASB 124 Related Party Disclosures; and
  - (c) There are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable.
- 
2. The Directors have been given the declarations required by section 295A of the Corporations Act 2001 from the chief executive officer and chief financial officer for the financial year ended 31 December 2011.

Signed in accordance with a resolution of the Directors:

A handwritten signature in blue ink that reads "James McBrayer".

**James McBrayer**  
Managing Director and CEO

Sydney, 27 March 2012

# Independent Audit Report



**Russell Bedford**

New South Wales

Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000  
Australia

T: +61 2 9032 3050

F: +61 2 9032 3058

E: [mail@russellbedfordnsw.com.au](mailto:mail@russellbedfordnsw.com.au)

W: [www.russellbedford.com](http://www.russellbedford.com)

## Independent Auditor's Report to the members of Cyclopharm Limited

### Report on the Financial Report

We have audited the accompanying financial report of Cyclopharm Limited, which comprises the consolidated statement of financial position as at 31 December 2011, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the company and the consolidated entity comprising the company and the entities it controlled at the year's end or from time to time during the financial year.

### *Directors' Responsibility for the Financial Report*

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error. In Note 2, the directors also state, in accordance with Accounting Standard AASB 101 Presentation of Financial Statements, that the financial statements comply with International Financial Reporting Standards.

### *Auditor's Responsibility*

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report. Our audit did not involve an analysis of the prudence of business decisions made by directors or management.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Member of Russell Bedford International – with affiliated offices worldwide

Liability limited by a scheme approved under Professional Standards Legislation

# Independent Audit Report

## **Independence**

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*. In addition to our audit of the financial statements we were engaged to undertake services disclosed in the notes to the financial statements. The provision of these services has not impaired our independence.

## **Auditor's Opinion**

In our opinion:

- (a) the financial report of Cyclopharm Limited is in accordance with the Corporations Act 2001, including:
  - (i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2011 and of its performance for the year ended on that date; and
  - (ii) complying with Australian Accounting Standards and the Corporations Regulations 2001; and
- (b) the consolidated financial report also complies with International Financial Reporting Standards as disclosed in Note 2.

## **Emphasis of Matter**

Without qualification to the opinion expressed above, we draw attention to Note 2 (b) 'Going Concern' in the financial statements, which identifies that the consolidated entity has incurred a loss of \$956,220 for the year ended 31 December 2011. These conditions, along with other matters as set forth in Note 2 (b) 'Going Concern', indicates the existence of a material uncertainty that may cast significant doubt about the consolidated entity's ability to continue as a going concern and whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial statements.

## **Report on the Remuneration Report**

We have audited the Remuneration Report included on pages 15 to 22 of the directors' report for the year ended 31 December 2011. The directors of the company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

## **Auditor's Opinion on the Remuneration Report**

In our opinion, the Remuneration Report of Cyclopharm Limited for the year ended 31 December 2011, complies with section 300A of the *Corporations Act 2001*.

RUSSELL BEDFORD NSW  
Chartered Accountants



WALI AZIZ, B.COM, CA  
Associate

Dated this 27<sup>th</sup> day of March 2012  
Sydney

# ASX Additional Information



The following information is current at 29 February 2012

## A. SUBSTANTIAL SHAREHOLDERS

The following have advised that they have a relevant interest in the capital of Cyclopharm Limited. The holding of a relevant interest does not infer beneficial ownership. Where two or more parties have a relevant interest in the same shares, those shares have been included for each party.

| Shareholder                                   | No. of ordinary shares held | Percentage held of issued ordinary capital |
|-----------------------------------------------|-----------------------------|--------------------------------------------|
| Stinoc Pty Limited (a subsidiary of CVC Ltd)  | 44,174,864                  | 19.76%                                     |
| Chemical Trustee Limited                      | 40,000,000                  | 17.89%                                     |
| Barings Acceptance Limited                    | 31,846,991                  | 14.24%                                     |
| Lloyds & Casanove Investment Partners Limited | 23,542,876                  | 10.53%                                     |

## B. DISTRIBUTION OF EQUITY SECURITY HOLDERS

(i) Analysis of numbers of equity security holders by size of holding as at 29 February 2012

| Category         | Ordinary Shareholders |
|------------------|-----------------------|
| 1 - 1,000        | 5                     |
| 1,001 - 5,000    | 54                    |
| 5,001 - 10,000   | 47                    |
| 10,001 - 100,000 | 436                   |
| 100,001 and over | 117                   |
| Total            | 659                   |

(ii) There were 169 holders of less than a marketable parcel of ordinary shares.

## C. EQUITY SECURITY HOLDERS

| Twenty largest quoted equity security holders   | Ordinary shares<br>Number held | Percentage of issued shares |
|-------------------------------------------------|--------------------------------|-----------------------------|
| 1 STINOC PTY LIMITED                            | 44,174,864                     | 19.76%                      |
| 2 CHEMICAL TRUSTEE LIMITED                      | 40,000,000                     | 17.89%                      |
| 3 BARINGS ACCEPTANCE LIMITED                    | 31,846,991                     | 14.24%                      |
| 4 LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED | 23,542,876                     | 10.53%                      |
| 5 INDO-SUEZ INVESTMENTS LIMITED                 | 7,040,017                      | 3.15%                       |
| 6 NORMANDY FINANCE AND INVESTMENTS LIMITED      | 4,700,000                      | 2.10%                       |
| 7 MRS TERRI LAMBROS                             | 4,000,000                      | 1.79%                       |
| 8 DERRIN BROTHERS PROPERTIES LIMITED            | 3,720,000                      | 1.66%                       |
| 9 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED     | 2,966,994                      | 1.33%                       |
| 10 SOUTHGATE INVESTMENTS FUNDS LIMITED          | 2,625,000                      | 1.17%                       |
| 11 J K M SECURITIES PTY LIMITED                 | 2,000,000                      | 0.89%                       |
| 12 ABASUS INVESTMENTS LIMITED                   | 1,700,000                      | 0.76%                       |
| 13 CITY & WESTMINSTER LIMITED                   | 1,650,000                      | 0.74%                       |
| 14 SOUTH SEAS HOLDINGS PTY LTD                  | 1,500,000                      | 0.67%                       |
| 15 NEWRIDGE ENGINEERS LIMITED                   | 1,455,000                      | 0.65%                       |
| 16 OCI CONSTRUCTION LIMITED                     | 1,406,054                      | 0.63%                       |
| 17 MALACKEY HOLDINGS PTY LTD                    | 1,250,000                      | 0.56%                       |
| 18 NABIL AND HASMIK MORCOS                      | 1,058,297                      | 0.47%                       |
| 19 MR JOHN SHARMAN                              | 1,010,000                      | 0.45%                       |
| 20 MELBOURNE CORP OF AUSTRALIA PTY LIMITED      | 1,000,000                      | 0.45%                       |
|                                                 | 178,646,093                    | 79.90%                      |
| Other equity security holders                   | 44,933,325                     | 20.10%                      |
| Total                                           | 223,579,418                    | 100.00%                     |

## D. VOTING RIGHTS

The Company's constitution details the voting rights of members and states that every member, present in person or by proxy, shall have one vote for every ordinary share registered in his or her name.

# General Information



## **Directors**

### **Vanda Gould**

Non-Executive Chairman

### **James McBrayer**

Managing Director & CEO

### **David Heaney**

Non-Executive Director

## **Company Secretary**

James McBrayer

## **Registered Office**

### **Cyclopharm Limited**

Building 75  
Business & Technology Park  
New Illawarra Road  
Lucas Heights NSW 2234  
T: 02 9541 0411  
F: 02 9543 0960

### **Cyclomedica Australia**

Building 75  
Business & Technology Park  
New Illawarra Road  
Lucas Heights NSW 2234  
T: 02 9541 0411  
F: 02 9543 0960

### **Cyclopet**

Basement 2  
Macquarie University Hospital  
3 Technology Place  
Macquarie University NSW 2109  
T: 02 9878 3869  
F: 02 9889 1281

### **Cyclomedica Canada**

615 Old York Road,  
Burlington,  
Ontario L7P 4Y6  
Canada

### **Cyclomedica Germany**

Museumstrasse 69  
D-38229 Salzgitter  
Germany

### **Cyclomedica Europe**

Unit A5,  
Calmount Business Park  
Ballymount  
Dublin 12  
Ireland

## **Auditors**

Russell Bedford NSW  
Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000

## **Share Registry**

Gould Ralph Pty Ltd  
Level 42  
259 George Street  
Sydney NSW 2000  
T: 02 9032 3000  
F: 02 9032 3088

## **Bankers**

National Australia Bank  
Level 2, 151 Rathdowne Street  
Carlton VIC 3053

## **Solicitors**

Piper Alderman  
Level 24, 385 Bourke Street  
Melbourne VIC 3000

## **Stock Exchange Listing**

The ordinary shares of  
Cyclopharm Limited are listed on  
the Australian Securities  
Exchange Ltd (code: CYC).

This page has been intentionally left blank.